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Abstract
Aging-associated vision loss is increasingly prevalent in our population and intravitreal
injections are commonly used to administer ocular drugs to the posterior segment of the eye.
This work aims to visualize and predict the delivery of ocular drugs by combining microcomputed tomography (micro-CT) imaging and computational fluid dynamics (CFD)
modeling. Intravitreal injections were administered into ex vivo porcine eyes and imaged for
an extended period of time to track the progression of the injected drug mimic. Non-invasive
imaging allowed for precise determination of contrast agent concentration, flow patterns and
fate. A computational model was developed that provided quantitative agreement with the
concentration values found in the experimental study and allowed for easy manipulation of
parameters. The ability to accurately model drug transport following an intravitreal injection
provides vital information to better understand the specific concentration and time frame for
the drug to reach the target site.

Keywords: intravitreal injection, drug delivery, vitreous, diffusion, micro-computed
tomography, computational fluid dynamics
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Chapter 1
Introduction

Developing greater insight and understanding into the processes involved in ocular drug
delivery, particularly in the posterior segment o f the eye, is vital information when
developing drugs and drug delivery systems. This chapter provides the motivation o f the
work to be presented and background o f eye anatomy, ocular drug delivery, imaging
modalities and computational flu id dynamics. An outline o f the hypothesis, objectives and
experimental design provide the rationale o f what will be presented in the following
chapters.

1.1

Background and Motivation

Every 12 minutes someone in Canada develops significant vision loss. Vision loss
accounts for the highest health care costs compared to any other disease in Canada,
including diabetes, cardiovascular disease and cancer.1 The leading cause of vision loss
and legal blindness in people over the age of 50 in the developed world is age-related
macular degeneration (AMD).2,3 AMD is a chronic degenerative disease that affects a
small area at the back of the eye called the macula and it is this region of the eye that is
responsible for central vision. Advanced stages of AMD cause complete loss of central
vision, while some peripheral vision is maintained. A person’s quality o f life is
significantly reduced when affected by vision loss, such as AMD.4'6 AMD and other
ocular diseases associated with the posterior segment of the eye, such as diabetic
retinopathy, macular edema and retinal vein occlusion, are commonly treated by
administering injected drugs directly into the eye.
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Figure 1.1 Anatomy of a normal human eye.
Adapted from: National Eye Institute, National Institutes of Health.

1.1.1 Eye Anatomy
Important anatomical features of the human eye for the purpose of this work are shown in
Figure 1.1. Ocular anatomy is typically divided into two groups: anterior and posterior.
The anterior region encompasses the region between the cornea and the lens. The cornea
is the outermost layer o f the anterior segment of the eye and is most useful in orienting
the front of the eye. Light first passes through the cornea and then the lens, which focuses
the light onto the back o f the eye, specifically the retina. The posterior region includes the
sclera, vitreous and retina The sclera is the white covering of the eye that acts as a
protective layer and helps maintain the shape. Within the eye is the vitreous cavity which
contains the vitreous body (or humor), a jelly-like substance. The vitreous is enclosed by
a membrane called the hyaloid membrane. The anterior hyaloid membrane separates the
vitreous from the anterior chamber and the lens. An important function of the vitreous
body is to hold the retina against the back of the eye. The retina is a very thin multi-layer
o f cells at the back of the eye that is responsible for detecting the light and transmitting
the image to the brain via the optic nerve. The small specialized region of the retina
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responsible for detailed central vision, called the macula, is located near the center o f the
retina. At the center of the macula is the fovea, where the highest density of
photoreceptor cells are found and our sharpest and most brilliantly coloured vision
occurs.

1.1.1.1

Vitreous Body

The adult human vitreous has a length (from back of lens to retina) of around 16.5 mm,
weighs approximately 4 grams, and occupies a volume of about 4 ml. The primary
structural components, type II collagen and hyaluronic acid, occupy less than 1% of the
total volume of the vitreous.

The rest of the vitreous is composed of water. The

chemical composition of a typical human vitreous and the distribution of these
components are not homogenous.10 The mature vitreous is a transparent gel with
viscoelastic rheological properties. Rheological values for human vitreous have been
shown to be a function of region. The normal human vitreous has a density close to that
o f water (1 g/ml) and a kinematic viscosity of approximately 1.41 O'4 m2/s. The normal
postnatal vitreous is a homogenous gel and the fundamental aging process consists of a
progressive disintegration of the gel structure, particularly at the center of the vitreous.11
This process is termed vitreous liquefaction and starts early in life. Liquefied vitreous has
a viscosity closer to 10' m /s.

The large volume and gel structure of the vitreous,

consisting of several large molecular weight polymeric elements, suggests that its
function is to provide a system that absorbs mechanical stress and protects the
surrounding tissues during eye movement and physical activity. The vitreous
accomplishes its mechanical function by securing the retina’s adherence to the outer
layers and filling up the vitreous chamber, and acting as a barrier between the anterior
n

and posterior segments o f the eye for heat and drug transport.
There are several vitreous factors that affect the success or failure of drug delivery in the
eye. The vitreous body is relatively inert connective tissue and is quite porous and thus
transmits the pressure from the anterior chamber throughout the interior of the eye.12 It
has been observed that a needle hole in the sclera can affect transport between the
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aqueous and vitreous bodies.13 Many existing works consider diffusion to be the greatest
contributing factor to drug flow in the vitreous,14’15 over other transport mechanisms such
as convection. The degree to which convection is responsible has been shown to vary
with drug size and eye species. ’ An important factor to consider when dealing with
elderly patients is that their vitreous will be liquefied to some extent and may be less
efficient as a transport barrier.11

1.2 Ocular Drug Delivery
Drugs can be introduced into the eye by a variety of routes. The regions to which delivery
o f the drug is targeted and in which it is administered are divided in the same way as the
eye is anatomically, into anterior and posterior. Drug delivery to the anterior region is
typically administered by topical eye drops or subconjunctival injection and used to treat
diseases such as glaucoma, infection and inflammation. Administration of drugs to the
posterior region is accomplished using systemic administration, topical delivery and
direct injection. Diseases that require administration of drugs to the posterior segment
include AMD, diabetic retinopathy and uveitis.
Drug delivery in the eye poses a number of challenges including, but not limited to,
corneal barrier,

high aqueous humor turnover,

blood-aqueous barrier and blood-retina

barrier.19 Significant work has been devoted to developing and improving drug delivery
systems for the eye. Methods that have been developed recently, but not yet common in
clinical practice, include intraocular implants,
implants,

01

micro- and nanoparticle

intraocular pumps.

sustained release biodegradable
00 04

extended-release drugs '

and implantable

These remain as potential options in future clinical use, but all rely

on the transport properties of drug flow in the vitreous. Combined with this reason and
that intravitreal injections are currently very common in the clinic, intravitreal injections
will be the route of choice in this study’s experimentation.
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1.2.1 Intravitreal Injections
The first choice for administering drugs to the posterior segment of the eye is via
intravitreal injections.

Intravitreal injections are a direct needle injection into the eye

through the region called the pars plana, where the cornea meets the sclera. The drug is
administered into the human vitreous in volumes of 30-100 pi. This volume of drug is
expected to reach the target site, commonly the retina, by means of diffusion and
convection. It has been estimated that intravitreal drug transport in humans is composed
o f 30% convective flow and the remainder diffusive flow.16 The challenge of intravitreal
injections is due to the large diffusion distance in which the drug must travel. When
administering a small volume of drug in a relatively large region, the challenge becomes
the delivery o f sufficient drug concentration to the correct region. The desirable fate of
the drug is to be present at the target site, specifically the macula in treatment o f AMD, at
a therapeutic level of concentration for a sufficient time period without reaching levels of
toxicity.27,28
Intravitreal injections remain the most commonly used method of administering drugs to
the posterior segment of the eye. Despite the invasive nature of the injections there is a
low rate of complications, such as inflammation, cataract and retinal detachment, that
result.29,30 The number of intravitreal injections being completed in Canada has increased
dramatically since 2003. In Ontario between 2005 and 2007, the rate of intravitreal
injections grew 8-fold from 3.5 to 25.9 injections per 100 000 patients per month.

•2 1

This

has been attributed to the increased development of intraocular drugs, specifically those
for the treatment of AMD.

1.2.2 Drugs Administered by Intravitreal Injection
Recent development of drugs for intravitreal injection have provided a variety of
treatment options for diseases such as AMD. Each drug has unique properties, such as
molecular weight, that may affect its transport properties in the vitreous. Table 1.1 lists
the drugs used in the treatment of AMD via intravitreal injection and characteristics
found in the prescribing information sheets.
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Intravitreal injection volumes and doses administered in humans for the treatment of
AMD range considerably between drugs. Taking into account the typical volume of
vitreous in humans, this translates into a large difference in the concentration, from 3.47
to 25 mg/ml, in which the drugs listed in Table 1.1 are administered. The ability to
optimize this concentration is vitally important in order to be effective in treating the
disease while not reaching levels of toxicity.

Table 1.1 Age-related macular degeneration drugs
Characteristics of drugs used in treatment of age-related macular degeneration
administered via intravitreal injection___________________________________
Molecular
Weight
(kDa)

Volume
(ul)

Concentration
(mg/ml)

Dose

Pegaptanib
(Macugen®)32

50

90

3.47

0.3

Bevacizumab
(Avastin®)33

149

50

25

1.25

Ranibizumab
(Lucentis®)34

48

50

10

0.5

Drug

(mg)

Aflibercept
0.5-2
(VEGF
110
Trap-Eye)*
*Aflibercept (VEGF Trap-Eye, Regeneron Pharmaceuticals Inc) is currently in clinical trials for
the treatment of AMD, diabetic macular edema and central retinal vein occlusion and specific
prescribing information is not yet available
-

1.3

-

Imaging

With the development of specialized imaging modalities such as molecular imaging,
optical coherence tomography, positron emission tomography, magnetic resonance
imaging (MRI) and micro-computed tomography (micro-CT), we are now able to noninvasively gain detailed information from biological systems. All modalities are useful
tools in retrieving data on drug delivery, distribution and elimination. MRI is particularly
useful for soft tissue imaging, but has limitations of low spatial resolution and long scan
times,35,36 which are both very important components when studying ocular drug
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delivery. In this study, micro-CT was chosen as the non-invasive imaging modality for
tracking drug delivery in the eye for its high spatial resolution and fast scan time.

1.3.1 Micro-Computed Tomography
Micro-CT is an x-ray based imaging system that combines x-ray transmission with
computed tomographical reconstruction to provide three-dimensional (3D) image
volumes. An x-ray source transmits a beam of photons through the specimen and
generates a set of 2D radiographs. These 2D radiographs are reconstructed into grey-scale
images that are based on the tissue electron densities and level of photon absorption.
The set of 2D images are further reconstructed into a 3D volume for further analysis. CT
contrast is achieved though the difference of the x-ray photon attenuation between
materials. Attenuation is the decrease in the number of photons as the x-ray beam passes
through material as a result of scattering or absorption. Heavy elements have a high
attenuation primarily due to the absorption of the x-ray photons while soft tissue has a
low attenuation due to the transmission of x-ray photons through the material.
Attenuation therefore leads to image contrast in CT imaging.
For the purpose of this study, the delineation of anatomical features is not as important as
visualizing the injected drug mimic. Major anatomical features such as the cornea, lens
and sclera were all visible in the reconstructed CT images and provided useful landmark
information. Radiopaque contrast agents with high atomic number and density,
characteristics of high attenuation, were chosen to be used as drug mimics for clear
differentiation from surrounding tissue and background. Specific concentrations can be
measured by taking advantage of the linear relationship between attenuation and contrast
agent concentration in x-ray imaging and is the basis of this study.38,39 Micro-CT has
been shown to have the capabilities in providing advanced analytical techniques and
detailed internal quantitative information to investigate drug delivery.40
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1.4 Computational Fluid Dynamics
Computational fluid dynamics (CFD) is a method of modeling fluid transport using
numerical analysis. CFD is made up o f three different disciplines: engineering (fluid
dynamics), mathematics and computer science.41 Fluid dynamics encompasses the study
o f fluids either in motion or at rest and how they interact with other processes such as
heat transfer and chemical reactions. Transport properties (i.e. diffusion coefficient,
density, viscosity) are used to describe the fluid under study within the simulations in the
mathematical equations. The mathematical equations are used to describe the fluid’s
characteristics, such as concentration and flux, based on the transport properties input
into the equations. It is the computational aspect that combines it all together into an
efficient software package.
The use of CFD for modeling ocular drug flow provides the capability to manipulate a
variety of transport properties and investigate the extent to which they are important in
the mechanisms of drug delivery. All o f this can be completed without the use of animals
or humans and allows for a cost-effective method of studying ocular drug flow. However,
it is important to develop a CFD model that is based on experimental evidence and can be
validated. With a physiologically relevant model, realistic predictions can be made by
running a simulation and provide insight into ocular fluid dynamics that may not be
realized in any other way.15

1.5 Objectives
The global objective o f this work is to gain a better understanding, through the
integration of imaging and modeling, of drug distribution and fate in the eye when
administered to the posterior segment
The specific objectives are:
•

To compare the x-ray compatibility and transport properties of contrast
agents, acting as drug mimics, in the vitreous body of the eye.
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•

To characterize and understand the transport properties of a drug mimic in
the vitreous body using micro-computed tomography imaging.

•

To examine any unexpected characteristics arising from intravitreal
injections that could impact ocular drug delivery.

•

To develop a computational fluid dynamics model based on data from
micro-computed tomography images.

1.6

Hypotheses

Transport properties will vary between contrast agents due to differences in molecular
weight and will be able to be visualized and calculated using image analysis o f micro-CT
images. Imaging of the eyes before, after, and in some cases during injection, will allow
for full assessment of the injection outcomes and reveal details of any potential
complications. Computational fluid dynamics will provide a time dependent model of
drug flow in the vitreous with concentration profiles that reflect those of the ex vivo
imaging results.

1.7

Experimental Design

X-ray compatibility and transport properties will be assessed using micro-CT imaging.
Measures of signal intensity, clearing time and diffusion coefficients will be analyzed and
compared between differing contrast agents and concentrations. The iodinated contrast
agent will be studied as a possible drug mimic and the gold nanoparticles will be studied
as a drug mimic and as a drug tag. It is expected both contrast agents will provide
visualization within the vitreous, but the transport properties, such as the diffusion
coefficient, are expected to differ due to the material properties, such as the large
difference in molecular weight between the two agents.
Micro-CT will allow for non-invasive analysis of an injected bolus of the drug mimic
over an extended period of time. Each eye will be monitored for the full duration of the
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scanning, providing a complete temporal data set per eye. Calculation and analysis of the
diffusion coefficient will be completed and will be instrumental in understanding the
mechanisms of diffusion in intravitreal drug transport.
Anomalous features have the potential to impact ocular drug delivery. Some
characteristics not expected to be seen following an intravitreal injection are identified
and analyzed. Air bubbles and their fate within the vitreous, needle tip movement during
the injection resulting in an altered bolus shape and jetting from the tip of the needle, can
all impact the transport of drugs in the vitreous. A better understanding of how they may
influence drug flow and possible ways to eliminate them will be identified in an effort to
optimize intravitreal injection techniques.
Utilizing the data acquired from non-invasive imaging, a computational fluid dynamics
model is developed based on experimental results. Using the knowledge from the microCT experiments with that of the literature, a model of drug flow in the vitreous can be
used to complete theoretical studies using different drug properties and eye parameters. It
is expected the computational fluid dynamics model will provide strong correlation to the
experimental results and allow for validation of the model. The combination of noninvasive imaging and computational fluid dynamics provides a unique combination of
resources to study drug distribution and fate in the eye. Combing these methods with
what is currently known of intravitreal injections and associated drugs, new methods and
tools can be developed for studying intravitreal drug delivery.

Inject ex vivo
porcine eyes

Micro«CT image
acquisition

Reconstructed CT
images

I
Model
simulation

Model
development

Diffusion
calculation

Figure 1.2 Experimental design flow chart
The general study design to address the objectives presented and create a link between
non-invasive micro-CT imaging data and computational fluid dynamics modeling in
shown in this flow chart.
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Chapter 2
2

Comparison of radiographic contrast agent drug mimics
in the vitreous

The purpose o f the work presented in this chapter is to compare the x-ray compatibility
and transport mechanisms o f two contrast agents acting as drug mimics. Iodine based
(Omnipaque™) and gold nanoparticle (AuroVist™) contrast agents were studied using
micro-CT imaging. Comparisons o f signal intensity, dilution in the vitreous and
molecular weight are made to demonstrate their effectiveness in use as an intravitreal
injection drug mimic or agent acting as a tag fo r a clinical drug.

2.1

Introduction

With an increasing number of intravitreal injections being administered1 and more drugs
being developed for use in the vitreous of the eye, there is a requirement to know the flow
and fate patterns of these drugs. In studying ocular drug transport, it is vitally important
to maintain the integrity of the eye and not disrupt its normal state. Non-invasive imaging
is appropriate since it allows for each specimen to be used for its own control and can be
longitudinally monitored.2 This has been recently made possible with the development of
non-invasive imaging techniques, such as micro-computed tomography (micro-CT).
Micro-CT provides high resolution volumetric images, but provides poor soft tissue
contrast. This limitation can be overcome using contrast-enhanced imaging to
successfully visualize the transport of an injected solution.
An injected contrast agent can be utilized to achieve higher contrast within a CT image.
Materials that have a higher atomic number (Z) have a higher contrast in x-ray imaging.
Iodine (Z = 53) is a commonly used material as a radiographic contrast agent. Iodine’s
high atomic number means it is a heavy element and therefore has a higher attenuation
coefficient. Iodinated solutions are an ideal contrast agent for clinical applications
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because they are water soluble making them highly compatible with biological systems.
Gold nanoparticles have recently become available as a new x-ray contrast agent. Gold
has a higher atomic number (Au 79 vs. I 53) and a higher absorption coefficient (at 100
keV: gold 5.16 cm2/g; iodine 1.94 cm2/g; soft tissue 0.169 cm2/g). This has been shown
•5

to account for about 3 times greater contrast per unit of weight of gold than iodine.
Drug administration via intravitreal injection relies on the assumption that the injected
drug will diffuse to the target site within the eye, rather than being injected at the exact
site. This is the case since the target site is very delicate retinal tissue and is a very small
location (5-6 mm macula diameter in humans). Since the drug must travel through the
vitreous to the target site, it is important to be able to visualize the contrast agent post
injection within the eye for several hours. Long scan times require a contrast agent that
will persist at a sufficient level of concentration to be imaged for the duration of the
entire study. It is also important to keep the intravitreal injection clinically relevant and
therefore at a volume that resembles that used clinically, which is approximately 50-100
pi for the human eye.4
Previous work has shown magnetic resonance imaging (MRI) can be used to monitor
r

n

ocular drug delivery using compatible contrast agents. ' MRI contrast agents used in
previous studies include manganese ion (Mn j , Mn

with ethylenediaminetetraacetic

acid (EDTA) chelate and gadolinium-diethylenetriaminopentaacetic acid (Gd-DTPA).
Mn2+ and MnEDTA2" are both small ions that would have very different transport
properties than macromolecules. Gd-DTPA is a macromolecule that should more closely
represent the flow characteristics of drugs used in intravitreal injections. MRI studies are
limited in that the spatial resolution may not be high enough to determine the
concentration or small volume of drug surrogates in thin tissues less than 0.3mm.

8

This study utilizes a non-invasive imaging modality that allows for rapid scan time and
high resolution. The purpose of this work is to compare the x-ray compatibility and
transport mechanisms of contrast agents acting as drug mimics as they flow through the
vitreous body of the eye. This is accomplished by the objectives of this work which are to
determine if gold nanoparticles are a useful radiographic contrast agent for visualizing an
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injected bolus within an eye over time and to determine the optimal range of
concentrations to use for intravitreal injections when studying drug transport and flow in
the eye.

2.2

Materials and Methods

2.2.1 Micro-Computed Tomography
Micro-computed tomography (micro-CT) scanning was performed using a pre-clinical
system (eXplore Locus Ultra, General Electric Healthcare Bioscience, London, Ontario,
Canada). The system provides the fast-scanning speed of a clinical scanner with the high
resolution of micro-CT and is designed for small animal experiments. It is this system
that will be utilized in future ex vivo and in vivo experiments looking at drug delivery in
the eye. A flat-panel detector mounted on a slip-ring CT gantry was used to acquire 3D
volumetric data in 8-16 seconds with an isotropic spatial resolution of 150 pm. The x-ray
tube voltage and beam current were kept constant during the experiments at 80 kVp and
the 80 mA, respectively.

2.2.2 Contrast Agents
Two commercially available contrast agents were chosen for this study. Iodine based
iohexol (Omnipaque™ 300, GE Healthcare, Oakville, Ontario, Canada) was chosen
because of its common use as a radiographic contrast agent both clinically and
experimentally and is very economical. Omnipaque 300 contains 300 mg of iodine per
milliliter and has the molecular weight of 821 g/mol. It has an osmolarity of 465
mOsm/L, absolute viscosity of 6.3 at 37°C and specific gravity of 1.349 at 37°C.
Gold nanoparticles (AuroVist™ 1102, Nanoprobes Inc, Yaphank, New York, USA) were
•5

chosen as they have been shown to provide higher contrast at lower concentrations. The
molecular weight of gold nanoparticles is much higher than iodine (50 kDa vs. 0.82 kDa)
and studies have shown this to attribute to a slower clearing time in biological systems.3
This provides for a longer period of contrast detection at a lower initial concentration. In
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addition, the 1.9 nm gold nanoparticles have a similar molecular weight as the most
common anti-VEGF drugs used to treat AMD.

2.2.2.1

Iodine and Gold Concentration Standards

Concentration standards were made using vials of varying iodine concentrations.
Solutions were prepared in the following concentrations: 300, 150, 75, 37.5, 18.75 and
9.375 mg/ml. The 300 mg/ml sample was full strength Omnipaque 300. The 150 mg/ml
solution was prepared by diluting 100 pi of full strength Omnipaque 300 with 100 pi of
Phosphate Buffered Saline (PBS) lx concentration. To prepare the 75 mg/ml solution 25
pi of Omnipaque 300 was diluted with 75 pi of PBS, the 37.5 mg/ml solution was 12.5 pi
Omnipaque to 87.5 pi PBS, the 18.75 mg/ml solution was 6 pi Omnipaque to 94 pi PBS
and the 93.75 mg/ml solution was 3 pi Omnipaque to 97 pi PBS. Two additional vials of
deionized water and air were included to assist with signal intensity calibration.
For concentration standards of gold nanoparticle solutions were prepared in the following
concentrations: 200, 134, 67, 33.5, 16.75 and 8.375 mg/ml. The 200 mg/ml solution was
prepared by diluting the 40 mg vial of gold nanoparticle powder with 200 pi o f PBS. The
134 mg/ml solution was prepared by taking 100 pi of the 200 mg/ml solution and diluting
it with 50 pi of PBS. This 1:1 dilution process was repeated to make the remaining
concentration solutions. Two additional vials of deionized water and air were included to
assist with signal intensity calibration.

2.2.3 Intravitreal Injections
Freshly harvested enucleated porcine eyes were obtained from a local abattoir and used
within 10 hours postmortem. During scanning and for the remainder of the study, they
were maintained at 24°C (+/- 2°C). Pre-injection scans confirmed no abnormalities in any
eyes. Iodinated and gold nanoparticle contrast agents were used as drug mimics at
varying concentrations. Clinically relevant intravitreal injections of a 30 pi volume of
contrast agent were administered into 24 enucleated eyes. The injection volume of 30 pi
was calculated based on the smaller vitreous volume of the pig eye compared to that of
the human. Injections were performed 2-3 mm posterior to the superotemporal limbus at
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a depth of 1 cm using 29-gauge needles (SS05M2913, Terumo Medical Corporation,
Somerset, NJ, USA).

2.2.4 Imaging
Scans were acquired up to 230 minutes (the anticipated time for the contrast agent to
remain at sufficient concentration and/or reach the retina) following the injection to allow
for visualization of the contrast agent’s progression through the vitreous. Concentration
standards were included in the scans for calibration purposes.

2.2.5 Image Analysis
3D computed tomography visualization and analysis software (MicroView 2.1.2, GE
Healthcare, London, Ontario, Canada) was used to analyze the reconstructed CT images.
The CT number and standard deviation for each concentration sample in the
concentration standards were recorded. Measurements were taken from the center of each
vial in a 2 x 2 x 2 mm region of interest and recorded in Hounsfield units (HU). Linear
regression analysis was used to determine the relationship between signal intensity and
contrast agent concentration. This was completed for both iodine and gold nanoparticle
samples.

2.2.6 Estimation of Diffusion Coefficients
The diffusion coefficient of Omnipaque™ in the vitreous was estimated using the WilkeChang correlation,9 since that value was not available from published literature. An
estimate was made based on Gd-DTPA, which has a similar molecular weight (936.0
g/mol vs. 821.1 g/mol). The diffusivity of Gd-DTPA in water is known to be 2.6><1 O'10
m2/s.10 The following correlation equation can be derived if it is assumed that the molar
volume of each species at its normal boiling point is proportional to its molecular
weight,11
D O m nipaque _
D Gd-DTPA

0.6

m w Gd-DTPA
;

,
^ M WOmnipaque
y

( 2 . 1)
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which yields 2.8X10’10 m2/s for Omnipaque in water. Since the vitreous is composed of
more than 99% water,12 this assumption was thought to be reasonable.
There is no empirical data to date for the diffusion coefficient of gold nanoparticles
(AuroVist™ 1.9 nm). Since the particles are close to spherical and are much larger than
the water molecules around them, the diffusion coefficient in water can be modeled using
the Stokes-Einstein equation,13

D=

RT
67iZrN

(2.2)

where R is the gas constant (8.3145 J/mol K), T is the absolute temperature (room
temperature = 295 K), Z is the viscosity of the diffusing medium (0.001002 kg/m s), r is
the radius o f the diffusing particle (1.5 nm) and N is Avogadro’s number (6.0221x 1023
per mole). The calculated value for 1.9 nm gold nanoparticles in water is 1.44x10'

m /s

with the assumption no aggregation occurs. This will be used as a comparison value to
those calculated for gold nanoparticles in the vitreous.

2.3

Results

2.3.1 Calibration
Calibration of the signal intensity with contrast agent concentration was determined using
the

standards

of various

concentrations.

The

concentrations

of both

iodine

(Omnipaque™) and gold nanoparticles (AuroVist™) along with air and deionized water
are shown in Figure 2.1.
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Figure 2.1 Vials of contrast agents containing varying concentrations
Reconstructed CT image of the calibration standards with vials of iodine (Omnipaque) in
the following concentrations 300, 150, 75, 37.5, 18.75, 9.38 mg/ml and gold
nanoparticles in the following concentrations 200, 134, 67, 33.5, 16.75, 8.38 mg/ml.
Vials of air and deionized water were also included with each sample for CT number
(HU) calibration.

The signal intensity, CT number (HU), is shown as a function of contrast agent
concentration (mg/ml) in Figure 2.2 for both iodine and gold nanoparticles. Linear
regression results for iodine can be expressed as an equation 5 = 31.9 ml/mg x C, + 956.0
HU, where S is the signal intensity and C, is the iodine concentration in mg/ml (r2 =
0.9892). For gold nanoparticles the result of linear regression is S = 31.0 ml/mg x Cg +
61.1 HU (r2 = 0.9993), where Cg is the gold nanoparticle concentration. These results are
indicative of a highly linear system (p < 0.01 and p < 0.0001, respectively). The yintercept is expected to be zero and for both contrast agents it was significantly different.
This was also reported by Du et al. that indicated the micro-CT scanner calibration may
need to be adjusted,14 but does not impact the results presented herein as our custom
concentration standards were used for calibration of the CT number with contrast agent
concentration.
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Figure 2.2 CT number and concentration calibration plot
Plot of measured CT number (signal intensity) versus known contrast agent
concentrations (circles, iodinated Omnipaque™; triangles, gold nanoparticle
AuroVist™). Linear regression results indicate a significant correlation is seen between
signal intensity and concentration for both contrast agents.

Calibration findings were compared to that of a study performed using the same microCT scanner and a custom made multiple parameter quality assurance phantom.14 The
linearity of the system was comparable between the two studies as all cases of
concentration standards exhibited strong linear regression. Measurements of signal
intensity in the water and air samples provided values shown in Table 2.1.
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Table 2.1 Comparison of CT numbers for air and water
Measured CT numbers (HU) and standard deviation (HU) of water and air used in the CT
calibration standards compared between previous studies (Du et al. 2007) and those used
in the current work.
Measured CT Numbers ± SD
Material

lohexol Standards

Gold Nanoparticle
Standards

-7 ±51

91 ±22

103 ±23

-909 ± 48

-1001 ±23

-1003 ±22

Du et al. 2007

Water
Air (central)
Air (peripheral)

-1003 ± 35

2.3.2 Contrast Dilution
The contrast agent in the eye was evalutated to determine if it was present at a sufficient
concentration to be detected for an extended period of time. Iodine solutions and gold
nanoparticles were monitored for up to 230 minutes at varying concentrations. The same
sagittal plane images of two specimens, one with an injection of iodine solution and one
with an injection of gold nanoparticles, were compared at the time points 8, 35, 195
minutes (Figure 2.3). Despite a small difference in initial concentration (37 mg/ml vs. 25
mg/ml) both specimens exhibited similar visualization of concentration at the respective
time points.
Quantitative analysis was completed using measured signal intensity values taken from
scans at each time point. The results are shown in Figure 2.4 with the maximum
detectable signal, representing the concentration within the scan, plotted against time.
Various concentrations were plotted to determine how the clearing profiles differed
between concentrations. The background signal in the image from vitreous had a mean of
210 ± 65 HU and was included in the graph. The iodine and gold nanoparticle solutions
were easily detectable at a signal intensity of greater than 500 HU.

25

Om nipaque™

AuroVist™

37 mg/ml

25 mg/ml

A

Lens

8 min

%

Lens

5m m

35 min

$

%

195 min

Figure 2.3 CT scan slices showing contrast agent in vitreous at time steps
Comparison of reconstructed micro-CT images taken in the same plane (sagittal) and
location at time points 8, 25 and 195 minutes between iodine based Omnipaque™ (37
mg/ml) and gold nanoparticle based AuroVist™ (25 mg/ml) indicates there is very little
difference in visualization of contrast between the two.
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Time (seconds)

Figure 2.4 Contrast agent dilution from the vitreous graphed over time
Comparison of contrast agent dilution within the vitreous based on the maximum
detectable pixel value (HU) at each time point indicates iohexol (Omnipaque™) and gold
nanoparticles (AuroVist™) follow different trends.

2.3.3 Molecular Weight
The molecular weight of the contrast agents and common intravitreal drugs were
compared alongside calculated diffusion coefficients (Table 2.2). Molecular weight
values were taken from product literature and diffusion coefficients were calculated
experimentally or taken from literature. Figure 2.5 shows the diffusion coefficients on a
logarithmic scale as a function of the molecular weight. The linear regression result is
also shown with the equation log(D) = -4.99xl0'3 1/kDa x MW+ 0.27 cm2/s (r2 = 0.674).
This shows that there is not a very strong linear relationship for the data points used, but
the values do lie within the 95% confidence interval.
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Table 2.2 Comparison of molecular weight and diffusion coefficient values
Diffusion coefficient values of Omnipaque™ and AuroVist™ are based on and
intravitreal drug values are based on literature and calculations.
Contrast Agent/
Drug

Molecular
weight
(kDa)

Diffusion coefficient in
water
(x 10^cm2/s)

lohexol
2.8a
0.82
(Omnipaque™)
Gold nanoparticles
1.44b
50
(AuroVist™)
Pegaptanib
0.66c
50
(Macugen®)
Bevacizumab
0.41d
149
(Avastin®)
Ranibizumab
0.67d
48
(Lucentis®)
a Wilke-Chang estimation
bStokes-Einstein estimation
c From Molokhia et al. using free aqueous diffusion coefficient estimation
d From S.K. Li et al. using dynamic light scattering measurements at 25°C

Figure 2.5 Diffusion coefficient and molecular weight linear regression
The relationship between diffusion coefficient (cm2/s) and molecular weight kDa) using
values from Table 2.2, r2 = 0.674. Dashed lines indicate 95% confidence interval.
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2.4

Discussion

Both contrast agents provided statistically significant linearity (p < 0.01) in signal
intensity and concentration analysis, as was expected and shown in previous work.14
Calibration is an important quality assurance step to the analysis of contrast agents,
especially when concentration information will be derived from the scans. It is also
vitally important not to rely on the same results for each successive scan (whether on the
same day or not). A simple and useful approach to receiving calibration information with
each scan is to include samples of diluted contrast agent vials, as was completed in this
study, with the specimen of interest and in the scanner’s field of view. The vials that were
made up for this study will be used in successive experiments looking at drug transport
following porcine eye injections.
The iodine and gold nanoparticle solutions can be detected at concentrations o f 9 mg/ml
and 3 mg/ml and greater, respectively, in the porcine eye. This is calculated using the
upper limit of the 95% confidence interval of the background (vitreous) and allows for
clear differentiation. Similar results were achieved of significantly higher contrast from
gold nanoparticles compared to iodinated solutions when equivalent molar concentrations
were used.15 To be able to visualize the contrast agent in the eye for a period of time, a
higher concentration would be required. The minimum concentration required is
dependent on the time in which one wishes to visualize the contrast agent. However,
Figure 2.4 provides useful information in determining this information and can be used as
a reference when choosing the initial concentration of the drug surrogate to inject into the
eye. One could use a significantly higher concentration to be confident sufficient contrast
is achieved, but when using a costly compound, such as gold nanoparticles, it is desired
to use the minimum amount necessary.
The most notable difference was that the gold nanoparticles rate of dilution was lower
than that of the iodine. This allows for lower concentrations of gold to be used in order to
obtain the same degree of signal intensity higher iodine concentrations would achieve.
This appeared to be in part due to the larger molecular weight of the gold nanoparticles
(50 kDa for gold nanoparticles vs. 0.82 kDa for iodine), since they do not move through
the vitreous as quickly. This observation has been shown before in pharmacokinetic
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studies.16,17 This is an important characteristic to point out as the molecular weight of
gold nanoparticles is the same or very similar to intravitreal drugs. Therefore, gold
nanoparticles acting as a drug surrogate provide a more representative example of how an
intravitreal drug such as Macugen® or Lucentis® would be transported in the eye. A
comparison of the molecular weight, typical injection volume, concentration and dosage
between surrogate contrast agents used in this study and common AMD drugs are
described in Table 1.1.
Gold nanoparticles allow for tagging to other agents, such as fluorescein and anti-bodies.
This provides greater capabilities in that multiple imaging modalities could be used to
investigate the drug flow, such as fluorescence microscopy or molecular imaging.3
Custom contrast agents could be developed where the gold nanoparticles are bound to an
ocular drug (ex. anti-VEGF) that would target the site of retinal disease (ex. macula).
Gold is available in a variety of sizes and forms, which would influence the visualization
and clearing properties. This also provides greater options in choosing a drug surrogate
and matching the properties to a specific drug.
A limitation of this work is the assumption that the contrast agents used act in the same
way as ocular pharmaceutical drugs used clinically. This was addressed by finding a
solution that was comparable in molecular weight to the most commonly used AMD
drugs. Molecular weight is only one pharmacokinetic property of a drug that may affect
18
its relationship with the vitreous, others include surface chemistry and drug elimination.
Since these findings are being used to investigate drug flow through the vitreous and
molecular weight has been shown to be a major influence on the drug’s elimination from
the vitreous,17,19 it can be assumed the contrast agents and ocular drugs would follow
similar pharmacokinetics.
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2.5 Conclusions
The necessary concentration and signal intensity information has been obtained allowing
for a direct comparison of iodine and gold nanoparticle solutions. It has been shown gold
nanoparticles have the ability to sustain contrast over an extended period of time, can be
used at lower concentrations than iodinated contrast agents, and closely resemble the
ophthalmological drug’s molecular weight. However, both iodine and gold nanoparticle
contrast agents can be successfully used to track a bolus through the vitreous and permit
more accurate predictions of the flow and transport mechanisms of intravitreal drug
delivery.
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Chapter 3

3

A framework for modeling ocular drug transport and
flow through the eye using micro-CT

This chapter describes the experimental design and analysis o f micro-CT imaging data
fo r assessment o f concentration and transport mechanisms o f ocular drug mimics
following intravitreal injection. Diffusion coefficients o f the injected iodine and gold
nanoparticle solutions were estimated using non-linear regression analysis with a
diffusion model. There was a predominantly diffusive component in the movement o f the
contrast to the back o f the eye in the horizontal (sagittal & coronal) directions, with
ultimate retinal fa te observed after 120 minutes. A real-time, accurate, non-invasive
method o f tracking a bolus and its concentration was achieved using a high spatial
resolution and fa st scanning speed micro-CT system.

3.1

Introduction

In a clinical environment, ocular drugs are often delivered topically as an aqueous eye
drop solution or by direct intravitreal injection. These delivery methods are inherently
pulsed with a short period of overdosing followed by a long period of underdosing.1 As
many drugs have a narrow therapeutic window of effectiveness and may be toxic at
higher concentrations,2 the ability to predict local drug concentrations is necessary for
proper loading of the delivery system. However, it has proven difficult to track and
predict drug flow and fate in vivo. Many drug delivery strategies are accepted because of
proven efficacy and an acceptable incidence of complications, but not based on a
thorough knowledge of the specific pharmacokinetic properties o f the eye and so
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potentially remain under-optimized. Though there is ample evidence to indicate that the
various therapeutic agents administered via intravitreal injection have an effect at the
retina,4'7 the details of drug delivery, transport and fate remain elusive. While there are
o

complications associated with intravitreal injections, it remains the route of choice for
administering certain therapeutic agents.9,10
The distribution of injected compounds in the vitreous has been studied both theoretically
and experimentally.11' 14 The first study to show experimentally measured concentration
distribution in the vitreous assessed the concentration of various injected fluorophores in
frozen sections of the vitreous.11 This model included examination of the effects of
intravitreal injection position and volume.15 Pharmacokinetic analyses of intravitreal
injections using bevacizumab (Avastin®) and ranibizumab (Lucentis®), two common
vascular endothelial growth factors (VEGF) inhibitors, have been conducted in rabbit
eyes.16,17 These studies involved euthanization of rabbits at various time points following
drug injection and measurement of drug concentrations in the aqueous fluid, whole
vitreous and serum. While such pharmacokinetic studies have yielded important
information, they provide little understanding of drug transport mechanisms through the
vitreous and retinal drug concentrations. A recent technique to examine molecular tracer
distribution in the vitreous involves snap freezing the whole globe to isolate the vitreous
after superficial thawing.18 This approach provides more information regarding vitreal
transport kinetics, but remains limited since it requires enucleation and significant eye
processing prior to drug transport assessments.
The techniques presented above have several important limitations. Those which involve
the use of fluorophores or dyes have the disadvantage of requiring enucleation for
analysis to re-enact the movement o f the substance in vivo. Most importantly, these
approaches also prevent real time or serial time point studies, and are unable to provide
drug transport gradients from the eyes of individual animals.19 Magnetic resonance
imaging (MRI) has been used to monitor the movement of a contrast agent within the
vitreous as a potential means to overcome these limitations. Three dimensional (3D) MRI
has shown significant differences between the concentration of gadolinium diethylene
triaminopentacetic acid (Gd-DTPA) within the vitreous when released from an episcleral
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implant in vivo as compared to diffusion in the ex vivo eye.19 Empirical data were then
used to calibrate a finite element mathematical model of the rabbit eye for simulation of
concentration profiles.

The study was limited however in that the temporal sampling

resolution required 26 minutes of imaging time to acquire a single time point and spatial
resolution was limited by a slice thickness of 1.0 mm.
Recent advances in micro-computed tomography (micro-CT) provide unique advantages
in pharmacokinetic studies of the eye including excellent temporal and spatial
resolution.

These systems have been shown to be particularly useful in providing real

time data on drug delivery and distribution in a non-invasive manner.

This combination

of parameters makes micro-CT in particular a more favorable option to study ocular
molecular transport over other imaging modalities that require a compromise between
'j'l

scan time, sensitivity and resolution.
The purpose of the work presented here was to create a method of measuring the
concentration and transport behavior of surrogate ocular drugs following intravitreal
injections. This has been accomplished by using ex vivo porcine eyes to study the
movement of a contrast agent within the vitreous. Porcine eyes were chosen for ex vivo
work because of their similarity in size and structure to the human eye24'27 and the ease of
access to large numbers of fresh enucleated eyes. Using the acquired data sets, diffusion
modeling was completed to achieve an improved understanding of the factors influencing
drug flow through the vitreous.

3.2

Materials and Methods

3.2.1 Micro-CT system
Scanning was performed using a pre-clinical micro-CT imaging system (eXplore Locus
Ultra, General Electric Healthcare Bioscience, London, Ontario, Canada). The system
possesses the capability of combining the high resolution of micro-CT with the fast
scanning speed of clinical CT. A flat-panel detector mounted on a slip-ring CT gantry
was used to acquire images with an isotropic spatial resolution of 150 pm. Each 3D
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volume was acquired in 8-16 seconds and provided a reconstructed 15 cm field of view
with axial extent of 15 cm. X-ray acquisition parameters (80 kVp and 40-80 mA) were
kept constant for each experiment.

3.2.2 Injections and Scanning
Enucleated porcine eyes were obtained from a local abattoir and used within 10 hours
postmortem. During scanning and for the remainder of the study, they were maintained at
24°C (+/- 2°C). An enclosed plastic case was used for simultaneous scanning of multiple
eyes while ensuring the eyes were stabilized, using 50 ml Falcon™ tube covers, and
hydrated, using PBS soaked medical gauze (Figure 3.1).
A baseline volume was obtained prior to injection of contrast agent to screen for
anatomical irregularity of the eyes.

Intravitreal injections of diluted iohexol, a low-

osmolar non-ionic iodinated contrast agent (Omnipaque 300, GE Healthcare, Oakville,
Ontario, Canada) and gold nanoparticle contrast agent (AuroVist™, Nanoprobes Inc,
Yaphank, New York, USA), were used as drug surrogates and tracer sources. To provide
quantitative measurements and analysis using the CT number in Hounsfield units (HU)
output by the system, standard solutions of known contrast agent concentrations were
scanned with the eyes for calibration purposes.
The intravitreal injection technique was taught by ophthalmologists and medical
residents, with a focus on mimicking a clinical injection to humans. All intravitreal
injections were performed manually using 0.3 ml syringes attached to 29 gauge needles
(SS05M2913, Terumo Medical Corporation, Somerset, NJ, USA). Each eye received a
single 30 pi injection o f a specified concentration. The needle was gently advanced
through the sclera approximately 2-3 mm posterior to the superotemporal limbus and
inserted to the appropriate depth of 1 cm (marked on the needle) to achieve a clinically
relevant mid-vitreous injection in the porcine eye. Contrast agent was injected and the
needle carefully withdrawn to minimize reflux along the in situ track. Immediately after
injections were completed, the case was carefully positioned in the micro-CT scanner.
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Experiments were performed with multiple eyes in the plastic case. Each eye received a
single injection of a specified concentration. Varying concentrations were used to
determine the effect of different dilutions in the transport of the drug surrogate for the
duration of the experiment. In the first experiment, a volume of 30 pi of iodine solution
was used in the following concentrations: 150, 75, and 37.5 mg/ml (n = 12). For the pilot
experiment, CT images were acquired at 12, 22, 32, 52 and 72 minutes (time 0 is at
injection of the first eye). 3D scans at varying time points allowed for the measurement of
the injected bolus’ movement in all directions. Based on the results identified in this pilot
experiment, all subsequent injections in the second experiment (n = 18) were carried out
with a volume o f 30 pi and at iodine concentrations of 150, 37.5, 18.75, 9.38, and 4.59
mg/ml. Images were acquired at 8, 12, 24, 36, 48, 96, 144 and 192 minutes post-injection.
Gold nanoparticle solutions were administered in porcine eyes (n=6) at concentrations of
100, 25 and 6 mg/ml. Images were acquired at 3, 5, 6, 8, 9, 11, 19, 35, 67, 131, 195, 230
minutes post-injection.

Figure 3.1 Enclosed container for ex vivo eyes in micro-CT scanner
An enclosed box was used to stabilize and the eyes in a closed environment for the full
duration of the experiment following intravitreal injections of contrast agent. A) The box
was designed to allow for multiple eyes to be scanned simultaneously and B) fit within
the scanner’s bore and field of view.
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3.2.3 Image Analysis
CT data were analyzed with dedicated 3D visualization and analysis software
(MicroView 2.1.2, General Electric Healthcare, London ON), which allowed the
specimens to be viewed as multi-planar reformats or as cross-sections through the axial,
sagittal and coronal planes (see Appendix A). After attainment of calibration curves to
correlate CT density to contrast concentration, HU attenuation of intra-ocular voxels was
converted to concentration units for further analysis.
Custom 3D regions of interest (ROIs) describing the spatial and temporal distribution of
contrast agent were automatically calculated based on CT numbers (HU) using
MicroView (see Appendix B). These regions were superimposed onto the image with
subsequent ROIs to show varying concentrations at a single time point. Alternatively,
ROIs for varying time points, but for a single concentration, were used to qualitatively
show the movement of an iso-concentration over time. Lastly, both of these scenarios
provide a means of measuring (ImageJ 1.41, NIH, Maryland, USA) the injected bolus’
changing concentration and movement over time.
The center o f the injected bolus was assumed to be the point that had the highest CT
number. This was found by creating a ROI around the bolus and generating a histogram
from MicroView that plots number of pixels versus CT number (HU). The location of the
greatest intensity was then used as the assumed center of the bolus. A line was placed in
the horizontal direction (coronal and sagittal) centered about the maximum value. A line
profile plot was created with CT number (HU) against distance. For the remaining time
points, the line profiles were placed in the exact same position of the scan to eliminate
errors caused by any potential movement of the bolus center (see Appendix C for further
information). These observed data were used to calculate the concentration profile of best
fit in the diffusion model.

3.2.4 Calculation of Diffusion Coefficients
A model for diffusion from an instantaneous spherical source was chosen from Crank
(1975) for the analysis of the intravitreal injection data. This model assumes that the

diffusing substance is moving uniformly through an isotropic infinite medium (r = 0 at t
= 0). The concentration Cr at radial position r at time t is given by
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where Co is the initial concentration throughout a spherical bolus with an initial radius a.
The analyses were based on the assumption that the injected bolus initially creates a
uniformly distributed 30 pi sphere in the vitreous.
Calculation of the diffusion coefficient (D) for each time point in both the sagittal and
coronal directions was made by fitting the experimental data with Equation 3.1. Analysis
was completed in MATLAB (R2009b, The Mathworks Inc., Natick, MA) where custom
code was used for background removal, data range selection, non-linear curve-fitting
using least squares method and regression analysis (Appendix D). This approach was
used to optimize the coefficient of determination (R ) of the curve fits and provide the
confidence intervals (Cl) at a significance level of 95%. Diffusion coefficient values were
selected for if an R2> 0.90 was achieved.

3.2.5 Reflective and Absorptive Boundaries
The behavior of the drug surrogate diffusion at a boundary, such as at the retina, was
studied using previously derived models. Mitra et al. (1993) presented the following
perturbation expansion of the non-Gaussian time dependent diffusion coefficient D(t) for
a finite spherical volume with a reflective (Equation 3.2) and absorptive (Equation 3.3)
boundary,29
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where Do is the diffusion constant of the bulk fluid, S/Vp is the ratio of surface area to
pore volume, t is time and a is the radius.
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3.3

Results

Reconstructed 3D images allowed for the visualization of contrast agent in the vitreous
following a mid-vitreal injection into ex vivo porcine eyes (Figure 3.2). Major features of
the porcine eye were also visible such as the cornea, lens and sclera. This allowed for
measurements of vitreous and lens dimensions to improve accuracy of future injections.
Injection concentrations of at least 6 mg/ml were sufficient to allow for visualization of
the injection in the vitreous, from the background, over an extended period of time. The
relationship between CT number (HU) and iodine concentration was calculated and
showed a very strong linear correlation (Figure 2.2), as expected. It was established that
measurable quantities of contrast agent began to reach the back of the eye (retinal
surface) after 2 hours (at a concentration of 6 mg/ml).

\

Sclera

Lens

|

Cornea

5 mm

Figure 3.2 Micro-CT image of ex vivo porcine eye
Reconstructed 3D micro-CT image of an ex vivo porcine eye with intravitreal injected
iodinated contrast agent (Omnipaque™) 12 minutes post-injection. Visible anatomical
features are labeled (cornea, lens, sclera).
The 3D surfaces of the injected bolus (ROIs) (see Appendix B), that were created to
represent the bolus, provided visualization of contrast concentrations at each time point.
For each eye specimen, several ROIs were superimposed to qualitatively show varying
concentrations at a single time point (Figure 3.3a). This provided an excellent means of
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viewing how the concentration of contrast was distributed within the bolus and the effects
of time. Alternatively, ROIs for varying time points and for a single concentration were
used to qualitatively show the movement of a single concentration over time (Figure
3.3b). Both of these scenarios provided a means of viewing the injected bolus’ changing
concentration and movement over time.

Figure 3.3 Isoshells representing concentrations in sagittal slice of micro-CT scan
A) 2D sagittal micro-CT image of ex vivo porcine eye following 30 jnl intravitreal
injection of iodinated contrast agent (Omnipaque™) with 3D regions of interest
representing specific concentrations from 6 to 105 mg/ml at 12 minutes post-injection.
B) 2D sagittal micro-CT image of ex vivo porcine eye following 30 pi intravitreal
injection of iodinated contrast agent (Omnipaque™) with 3D regions of interest
representing concentration shells of 10 mg/ml over a time period of 12-72 minutes.

Direct comparisons of the observed data and the predicted (Equation 3.1) have been made
for each specimen at all time points in which it was scanned. Figure 3.4 shows a typical
signal profile for the experimental and predicted data after 32 minutes, with the 95% Cl
around the fit. The R for this case was 0.991 and the confidence intervals are 91.503 HU,
which represents less than 0.6% of the maximum CT number (HU). In general, the
experimental data followed a Gaussian distribution curve and the time evolution of the
mass density functions is consistent with a diffusive transport process.
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Distance from center of bolus (mm)

Figure 3.4 Observed and predicted signal profile through bolus
2D signal profile at 32 minute time point displaying observed profile from micro-CT
image line profile (solid line) that was obtained through the center o f the injected bolus
and predicted profile from passive diffusion equation (dotted line) with 95% confidence
interval limits shown (dashed lines).

Diffusion coefficients were found from the optimal curve fits of the signal profiles. The
combined results for iodinated contrast agent tests are shown in Figure 3.5 for the 150
and 37.5 mg/ml initial iodine concentration, where the diffusion coefficients for the
horizontal (Figure 3.5a) and vertical directions (Figure 3.5b) are plotted against time. The
diffusion coefficients have a mean o f 4.76><10"4 mm2/sec and standard deviation of
7.79xl0'5 mm2/s for 150 mg/ml iodine concentration and 6.10xl0~4 ± 1.61x10“4 mm2/s
for 37.5 mg/ml concentration. The R2 values have a mean of 0.940 and a mean Cl of +/1.69% o f the maximum CT number. The diffusion coefficient values lie slightly above
the Wilke-Chang estimation (2.8x1 O'4 mm2/s). It should also be noted that they appear to
reduce with time and there are fewer values that meet the R2 > 0.90 criteria at later time
points.
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Figure 3.5 Iodine solution diffusion coefficients
Plot of calculated diffusion coefficients in the A) horizontal direction and B) vertical
direction of iodine at 150 (closed circle) and 37.5 mg/ml (open triangle) concentration in
vitreous against time in which micro-CT scans were acquired. Values are compared
against the Wilke-Chang estimation (dashed line).
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B

Figure 3.6 Gold nanoparticle diffusion coefficients
Plot of calculated diffusion coefficients in the A) horizontal direction and B) vertical
direction of gold nanoparticles at 10 (closed circle) and 2.5 mg/ml (open triangle)
concentration in vitreous against time in which micro-CT scans were acquired. Values
are compared against the Stokes-Einstein estimation (dashed line).
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Diffusivity values o f gold nanoparticles in the vitreous are shown in Figure 3.6 for 10 and
2.5 mg/ml concentrations in the horizontal (Figure 3.6a) and vertical (Figure 3.6b)
directions. The diffusion coefficients for the gold nanoparticles have a mean o f 6.72x1 O'4
mm2/sec and standard deviation of 3.20X10“4 mm2/s for the 10 mg/ml concentration and
9.07x1 O'4 ± 7.60x1 O'4 mm2/s for the 2.5 mg/ml concentration. The R2 values have a mean
o f 0.940 and a mean Cl of +/- 3.30% o f the maximum CT number. Diffusion coefficients
for gold nanoparticles appear to approach the Stokes-Einstein estimation (1.44x1 O'4
mm /s) with time.
The average normalized diffusion coefficients for iodine and gold nanoparticles solution
in the vitreous are plotted against length characteristic diffusion 1/2(D0f f 12 in Figure 3.7
and have been compared using the reflective (Equation 3.2) and absorptive (Equation 3.3)
boundaries analysis. It has been assumed that bulk diffusion Do = 6x1 (f4 mm2/s and the
bolus center is 4-7 mm from the retina. This model suggests that the retinal zone is acting
like a reflecting boundary and affecting the estimated diffusion coefficient.
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B

Figure 3.7 Reflective and absorbing diffusion
Average normalized diffusion coefficients plotted against length characteristic diffusion
for experimental values of A) iodine (150 mg/ml) and B) gold nanoparticles (10 mg/ml)
in the vitreous in the horizontal direction, sagittal (closed circles) and coronal (open
circles), compared against numerical simulations of reflective (solid curve) and absorbing
(dashed curve) for a spherical pore.
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3.4

Discussion

The framework developed in this study has enabled real-time tracking o f a contrast agent
bolus, delivered as a drug mimic via intravitreal injection, through the vitreous to the
desired retinal fate. The framework permits not only visualization of the bolus in the
same specimen over an extended period of time, but also quantitative evaluation of the
bolus evolution.

3.4.1 Capabilities of Micro-CT in Ocular Drug Transport Study
Recent studies attempted determination of the distribution of drug surrogates in the eye
following intravitreal injection in vivo, but failed to provide coupled spatial and temporal
information.30 The necessary spatial resolution was achieved in the work presented by
using a pre-clinical micro-CT scanner, rather than MRI. ’ With CT, it was possible to
estimate concentrations of contrast agents to within +/- 0.027 mg/ml over a range of 6 to
300 mg/ml for iodine and 3 to 150 mg/ml for gold nanoparticles with a spatial resolution
o f 150 pm. The pre-clinical micro-CT scanner also provides the necessary fast scanning
speed to achieve the temporal resolution required to model transport and flow within the
eye. The same specimen can be monitored almost continuously with scans acquired every
90 seconds over a number of hours. This approach allowed for the visualization of drug
surrogate concentration (Figure 3.3a) and movement (Figure 3.3b). Both of these
scenarios provided a means of viewing the injected bolus’ changing concentration and
movement over time. This is compared to the discontinuous data set achieved by
sacrificing many specimens at different time points, such as in snap freezing,

which

lacks consistency and reproducibility. Through the use of overlay in post-imaging
processing, such as Figure 3.3, it was found there is preferential flow in the vertical
direction and the drug surrogate closely followed the shape of the lens when the injection
site was near the lens. This study provides the proof-of-concept data that micro-CT
systems available today provide the high resolution, short scan times and near continuous
scan time points to accurately track contrast in the vitreous from delivery to target tissue
fate.

48

3.4.2 Modeling Ocular Drug Transport Using Experimental Data
The real-time empirical data acquired from the micro-CT scans of the injected intravitreal
bolus have enabled comparison with a ‘benchmark’ bulk diffusion model to aid the
interpretation of the results. Diffusion is thought to be the predominant transport
mechanism for ocular drugs through the vitreous humor and we have been able to
determine the apparent diffusion coefficients of iodine and gold nanoparticle solutions in
the vitreous of the eye. Micro-CT allows for simple measuring of the signal profiles in
any direction with a high resolution and sensitivity. These profiles can be used to fit a
mathematical model (Figure 3.4) and provide a means of calculating to what degree
diffusion is responsible in drug surrogate flow.
Average diffusion coefficients calculated for the iodine and gold nanoparticles did not
correlate with the expectation that they would be inversely proportional to the molecular
weight. The diffusion coefficient in the vitreous, when compared to an aqueous solution,
has been shown differ from the assumption of being inversely proportional to the
molecular weight.31 Both iodine and gold nanoparticles demonstrated time dependent
effects and at later time points approached the diffusion coefficients from Wilke-Chang
and Stokes-Einstein estimations, respectively. Density drive gravity flow in the vertical
direction could also be a contributing factor with higher concentration solutions. The
asymmetry and translation of the signal profiles (see Appendix C) and the reduction in
the magnitude of the apparent diffusion coefficients with time (as the overall bolus
concentration and specific gravity reduces with diffusion) support this hypothesis.
It can also be suggested that diffusion within a finite volume is affecting the behavior.
Diffusion coefficients that reduce with time could be a result of the drug surrogate
reaching a reflecting boundary, the retina. A number of researchers have investigated
diffusive phenomena in finite volumes, adjacent to absorptive and reflective
boundaries.32'34 The comparisons in Figure 3.7 show a reasonable match, thus this
appears to be a plausible hypothesis and is further supported by reductions in the R
values for the fits with the Gaussian model (Equation 3.1) at later time points.
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3.4.3 Limitations
A limitation of the current study is the use of contrast agents as drug mimics for ocular
drugs. Omnipaque was chosen as the contrast agent in these experiments due to its
common use with micro-CT applications and well-defined properties, reliability and cost
effectiveness. Gold nanoparticles have a closer molecular weight to common intravitreal
drugs and has been shown to be a suitable source of contrast and a tracer to allow proofof-principle tests to be realized. Modifying ocular drugs (bevacizumab or ranibizumab)
for detection in future micro-CT scanning is essential to provide clinically relevant
information on drug transport mechanisms. In particular, stability, density, molecular
weight and ionic charge of compounds can have significant effects on the observed
behavior. A competing set of criteria for using the micro-CT technique requires
radiopaque drug surrogates at suitable concentrations for visualization, but these must
also be balanced by clinically relevant volumes and concentrations.
The likely significance for in vivo studies has yet to be determined, since both diffusive
and advective flow will be occurring. ’ This ex vivo study elucidates diffusion effects
and can be deconvolved from future in vivo work to correctly understand the role of
advection. Further work will also involve the development of more sophisticated
computational fluid dynamics approaches to provide further understanding of the time
dependent coupled diffusion and advection transport behavior in a finite volume.

3.5

Conclusions

Mid-vitreous injection of iodinated and gold nanoparticle contrast agents as a drug mimic
using ex vivo porcine eyes and micro-CT scanning provides an accurate high resolution,
non-invasive method of spatial and temporal tracking of the bolus and concentrations.
The ability to extrapolate pharmacokinetic profiles from any region of the vitreous at
various time points provides extensive information in understanding ocular drug flow.
Our data show the effects of diffusion and boundary reflection on the movement of the
solutions in the vitreous body. Knowledge that a drug compound is reaching the retina at
a specific concentration and at a particular time after injection is vital information that
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has not been visualized to date. The results shown have provided the required ex vivo
proxy to apply the framework to in vivo experiments in rabbits. This work has provided
the initial steps towards a better understanding of the mechanisms of drug transport when
administered through the vitreous using micro-CT scanning.
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Chapter 4
4

Identification of anomalous features of intravitreal
injections using micro-computed tomography

This chapter describes the identified anomalous features that impact drug delivery in the
eye as a result o f an intravitreal injection.

Three-dimensional micro-computed

tomography images were used to detect characteristics not normally identified or studied
following an intravitreal injection. The presence o f air bubbles and inconsistent bolus
shapes have indicated that intravitreal injections have high variability. It is only through
the realization o f these anomalous features that the efficacy o f intravitreal drug delivery
will be improved through a consistent and accurate injection technique.

4.1

Introduction

Intravitreal injections remain a common technique for administering ocular drugs to the
posterior segment of the eye, especially for treatment of age-related macular
degeneration. Aspects of intravitreal injections, such as drug reflux, leakage from the
needle tract and needle depth, are known to be of importance for the efficacy of
intravitreal drug delivery . 1 Although, several types of symptomatic complications have
been shown to occur as a result of these injections.2' 4 With improved efficacy through
injection technique, it is expected there would be a reduction in the number of
complications associated with intravitreal injections.
Some complications that are less studied are the introduction of air or silicone into the
eye. Air bubbles have been previously documented and are seen clinically following
intravitreal injections, 5 but there has been little reporting on the size and fate of these air
bubbles. Other clinical reports have found intravitreal silicone oil droplets present within
the eye following intravitreal drug injections. ’ These are believed to have originated
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from the needle as a result of the manufacturing or repackaging processes. Any factors
that may affect the therapeutic efficacy o f the drug being administered by intravitreal
injection, such as the introduction of bubbles in the vitreous, should be addressed.
Pharmacokinetics in the vitreous is influenced by a number of factors. The more wellknown and understood include molecular size of the drug ,9’10 vitreous liquefaction, 11
vitreous volume , 12 intraocular pressure 13 and intraocular inflammation . 14 Some factors,
such as vitreous liquefaction or volume, cannot be changed through treatment options.
The differing properties of the vitreous as a result of vitreous heterogeneity 15,16 can
significantly alter how a drug travels through the vitreous in terms of time and route. The
distribution of drug in a liquefied vitreous has been shown to be faster than that of a
normal vitreous 17 and the effect on drug kinetics is largely influenced by the location of
liquefaction.

18

Many pharmacokinetic modeling studies, and therefore drug dosages, are administered
based on assumptions of a specific bolus shape 19,20 and location of injection, 21 but
deviations from these assumptions and predications change the flow and dosage window
of the drug. Therefore, the most efficient and effective outcomes for the target tissues
may not be realized. The purpose of the work presented in this chapter is to identify and
address anomalous features found following intravitreal injections using a porcine and
rabbit eye model. With direct spatial and temporal visualization of drug boli from
intravitreal injections using micro-computed tomography, we are better able to
understand the impact of anomalous features on drug delivery in the eye.

4.2

Methods

4.2.1 Micro-Computed Tomography
Micro-computed tomography (micro-CT) scanning was performed using a pre-clinical
system (eXplore Locus Ultra, General Electric Healthcare Bioscience, London, Ontario,
Canada). A flat-panel detector mounted on a slip-ring CT gantry was used to acquire
images with an isotropic spatial resolution of 150 pm. Each 3D volume was acquired in
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8-16 seconds and x-ray acquisition parameters (80 kVp and 40-80 mA) were kept
constant for each experiment.

4.2.2 Intravitreal Injections
Freshly harvested enucleated porcine eyes were obtained from a local abattoir and used
within 10 hours postmortem. During scanning and for the remainder of the study, they
were maintained at 24°C (+/- 2°C). Pre-injection scans confirmed no abnormalities in any
eyes. Iodinated (Omnipaque™ 300, GE Healthcare, Oakville, Ontario, Canada) and gold
nanoparticle (AuroVist™, Nanoprobes Inc, Yaphank, New York, USA) contrast agents
were used as drug mimics at varying concentrations. Clinically relevant intravitreal
injections of a 30 pi volume of contrast agent were administered into 24 enucleated eyes.
Injections were performed 2-3 mm posterior to the superotemporal limbus at a depth of 1
cm using 29-gauge needles (SS05M2913, Terumo Medical Corporation, Somerset, NJ,
USA). Each injection lasted for approximately 2 to 4 seconds.
An additional experiment was performed using ex vivo rabbit eyes to investigate the
effects of flow rate on intravitreal injections. Three groups of varying flow rates were
used and labeled as fast, intermediate and slow injections. Each set utilized three rabbit
eyes, one receiving an injection via a syringe pump (Harvard Apparatus PHD 4400 Hpsi,
Harvard Apparatus, Massachusetts, USA) and two receiving hand injections designed to
mimic a clinical injection. The syringe pump allows for a very accurate volume and flow
rate administration and provides the capability to exaggerate flow rates: fast (72 ml/hr),
intermediate (0.6 ml/hr) and slow injection (0.144 ml/hr).

4.2.3 Imaging
Scans of the porcine eyes were acquired up to 230 minutes (the anticipated time for the
contrast agent to remain at sufficient concentration and/or reach the retina) following the
injection to allow for visualization of the contrast agent’s progression through the
vitreous. Grey scale image intensity variations can be used to differentiate between
tissues in the eye and introduced fluids and gases. If used as a drug mimic, the temporal
and spatial changes in contrast agent concentration can also be observed as the fluid
diffuses through the vitreous.
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Experiments performed to investigate the flow rate of intravitreal injections were scanned
for up to approximately 20 minutes post-injection. Whole volume scans were acquired as
rapidly as possible. To allow for time for scanner start-up and data transmission, scans
could be acquired at a maximum rate of every 2-3 minutes.

4.2.4 Image Analysis
The acquired scans were reconstructed and analyzed using dedicated 3D computed
tomography visualization and analysis software (MicroView 2.1.2, GE Healthcare,
London, Ontario, Canada). Upon examination of the reconstructed scans, anomalous
features of air bubbles and irregular bolus shapes were realized.
To better understand the behavior of the air bubbles over time, measures of diameter
were taken using signal profiles and 3D regions of interest. The location of each air
bubbles was also recorded by its center x, y and z coordinates. All air bubbles resembled
perfect spheres and the volume was calculated using the sphere volume equation with the
measured diameter. Plots of bubble volume (F) with time (/) were produced and
assuming first order kinetics, the slope of these lines were found, providing the decay
constant (k), of the following exponential decay equation:
V = V 0-ekt

(4.1)

where Vo is the assumed initial volume of the bubble.
Analysis of the initial bolus shapes was completed by measuring the length, height and
width of a reference rectangular prism into which each bolus fit. It should be noted that
due to the irregularity of the shapes, these measures only provide an approximation of the
shape of the boli. Surface area of the initial bolus was calculated by creating a 30 pi
isosurface around the injected contrast agent. From this the surface area was
automatically calculated using an automated feature within the software.
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4.3

Results

4.3.1 Air Bubbles
Despite using typical clinical procedures to eliminate air from entering the vitreous
during hand injection (e.g. vertical positioning of needle, while tapping the syringe and
pushing out air), air bubbles were clearly visible within the vitreous (Figure 4.1) of 21
eyes following the injections and totaled 36 air bubbles.
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Figure 4.1 Air bubbles seen in micro-CT scan
Micro-computed tomography image showing air bubbles outlined as grey isosurfaces
found within the vitreous following intravitreal injection. Inset image is a 2D slice
through the injected contrast agent (white region) with the presence of an air bubble
(black circle).

The initial volume of the air bubbles ranged from 0.01 pi to 1.50 pi in volume and the
mean was 0.03 pi. Some movement (~ 1 mm in any direction) of the bubbles occurred
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over the scanning period of 230 minutes. The size of the bubbles was found to decrease
over this visualization period (Table 4.1).

Table 4.1 Air bubble changes over time in the vitreous
Air bubble characteristics and the changes over the period of 120 minutes post-injection.
5 minutes
post-injection

135 minutes
post-injection

1.78

1.38

0.06 ± 0.09

0.04 ± 0.07

Minimum

0 .0 1 0

0 .0 0 1

Maximum

1.483

1.421

Variable
No. per eye (mean)
Volume (pi)
Mean ± SD

Using the first order kinetics assumption, the decay constants of these bubbles (£) had a
mean of 0.0067 ± 0.0022 m in'1. Hence the bubbles had half-lives of 0.09 ± 0.02 days,
which is somewhat shorter than in vivo observations of free non-expansile gaseous
bubbles have found previously .22 This may be due to the size of the air bubbles; previous
studies have used large bubbles relative to the eye volume and the relationship between
surface area and volume is quite different for smaller bubbles. Further investigation of the
relative differences in half-life between different sized bubbles is shown in Figure 4.2,
where the decay in bubble volume with time is shown for four typical bubbles with sizes
ranging from 0.01 to 0.57 pi are shown. Each decay sequence has been fitted with
Equation 4.1 to find the half-life, which is seen to reduce with bubble size.
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Time (min)

Figure 4.2 Influence of time on air bubble volume
The relationship between air bubble volume (logarithmic scale) and time that was
observed in the micro-CT images following intravitreal injections. Lines indicate
calculated decay using Equation 4.1.

4.3.2 Bolus Shape
Many of the injected boli were found to have abnormal initial shapes (Figure 4.3). The
assumed shape of a sphere was rarely found; rather characteristics such as two conjoining
spheres or tear drop shapes often resulted. For an assumed sphere, the diameter would be
approximately 3.86 mm (based on 30 pi volume). However, the extent of the initial boli
had a larger range and a higher than expected average (Table 4.2). These asymmetric boli
were attributed to movement of the needle tip during the injection and reflux of the drug
mimic up the needle path. There was also no true center of the boli (i.e. no single region
with a peak contrast concentration) when the initial shape was abnormal.

61

Figure 4.3 Bolus shapes shown in micro-CT images
Micro-computed tomography images showing the abnormal shapes as a result of needle
movement during the intravitreal injection with the grey isosurface outlining the injected
contrast agent in three different specimens.

Table 4.2 Injected bolus dimensions
30 pi bolus shape dimensions in first scan after injection (5 minutes)
Length (m m )

Height (m m )

W idth (m m )

4.57 ± 1.01

5.67 ± 1.33

4.73 ± 2 . 1 2

M inim um

2.85

3.81

2.98

M axim um

6.39

8.49

4.92

Variable
M ean ± SD

4.3.3 Injection Flow Rate
The slow flow rate injection of 0.144 ml/hr, or for the duration of 12.5 minutes, provided
visualization of how the injected solution disperses into the vitreous to form an initial
bolus (Figure 4.4). Rather than forming a sphere at the very tip of the needle, the injected
solution forms up around the needle and disperses in a pattern to look like it is being
pushed away from the needle.
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Figure 4.4 Micro-CT images with needle in place during injection
Micro-CT imaging of intravitreal injection and bolus formation in the vitreous with the
needle in place during a 12 minute duration injection (0.144 ml/hr) using a syringe pump.

The slow and intermediate flow rates did not provide visualization of how the bolus
formed over time due to the temporal resolution limitations of the scanner. A scan was
completed in all cases immediately after the injection was completed and the surface area
of the 30 pi volume difference is shown in Figure 4.5. A 30 pi sphere would have the
surface area of 46.71 mm and is shown in Figure 4.5 as a means of comparison. There
does appear to be a trend of a higher surface area for faster injection flow rates. It was
observed that a higher injection velocity resulted in the drug being ‘pushed’ further into
the vitreous and therefore resulted in an unexpected initial shape and location. This was
evident in both the hand injections and syringe pump injection.
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Injection Length (sec)

Figure 4.5 Surface area of bolus compared with injection duration
Measured surface area of a 30pl injected bolus of contrast agent following an injection at
multiple flow rates (durations): 0.144 ml/hr (750 sec), 0.6 ml/hr (180 sec) and 72 ml/hr
(1.5 sec). A comparison was made with that of an ideal sphere with a volume of 30 pi
(dashed line).

4.4

Discussion

Although the presence of small air bubbles within the vitreous are not thought to be a
significant risk for patients, it is desirable to minimize their size, since they may cause
temporary vision impairment. In addition, the transport of the drugs from the injected boli
may be hindered due to the increased tortuosity of the diffusion/flow path around the air
bubbles. It is important to be aware o f the factors influencing pharmacokinetics so that
the standard method of drug administration is as effective as possible in disease
treatment. Whilst the air bubbles are likely to migrate upwards (due to buoyancy forces),
a patient’s position during and following the injection, in addition to pressure gradients or
flow in vivo, are also likely to affect air bubble movement. It was found that of the three
specimens used for syringe pump injection, none had evidence of air bubbles following
injection. Possible sources for these air bubbles may be inadequate de-airing of the needle
barrel system, cavitation or air entrainment during insertion.
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The most obvious source of the air bubbles would be transfer from the needle or the
barrel of the syringe. Interestingly, the initial volume of the air bubbles was found to be
quite large compared to the internal volume of the 29 gauge needles used (up to 5 to

6

times as great). Thus additional air may have been present in the syringe barrel, lying at
the interface of the rubber piston and the sides o f the syringe barrel. However, given the
care taken during preparation to remove air from the system and that the plunger was not
pushed completely to the end of the barrel during injections, this source of air is unlikely.
Hydrodynamic cavitation has been observed to cause microscopic air embolisms in other
forms of injection , 23,24 but it is not thought to occur with standard syringes and
injections.

However, it has been observed through micro-orifices and micro-fluidic

devices for low Reynolds number flows .26 Since the barrel-needle interface is defined as
a ‘sharp-edged orifice’ in flow terms, the sudden reduction in cross-sectional flow area
will induce a static pressure drop at the vena contracta (narrowing of flow) that occurs
just beyond the interface. If this drop is sufficiently large and the pressure begins to
approach the vapor pressure of the fluid, then cavitation and the growth of micro-bubbles
could occur in the flow. Whilst this mechanism is less likely for standard (4-5 second)
injection times, this cannot be discounted at this stage for shorter periods o f injection.
Confirmation of this phenomenon would require further careful study and complex multi
phase computational fluid dynamics approaches.
Another possible source of air could be entrainment during needle penetration of the
sclera. A number of examples of physical problems where small objects penetrate liquids
and films leading to air entrainment are described in the literature.

It is therefore

conceivable that surface tension forces at the air-liquid-needle interface are sufficient to
pull small volumes of air into the vitreous as the bevel and needle penetrate the sclera.
Further study of these injections in a sub-aqueous state would confirm this hypothesis.
Some prefilled syringes are available and useful in reducing or eliminating gas bubbles
from the syringe. The techniques in which the syringes are filled vary greatly and not all
methods are equally effective in removing air from the syringe barrel.

More advanced

vacuum filling provides bubble-free filling and therefore improves dosing accuracy,

65

product stability, improved sterility and no introduction of air during injection. Recent
work has shown foreign materials, such as silicone oil, may still be introduced during
O

intravitreal injections when using prefilled syringes. If hydrodynamic cavitation is the
source of air in the injection, prefilled syringes would not have any effect. Not all
prefilled syringes are manufactured and filled in the same way, but they do provide
potential for improving the efficacy of drug delivery in the eye.
Based on the observations of the resulting boli shapes after injection, delivery of the drug
cannot be based on predictions where the initial bolus is assumed to resemble a sphere.
Further experimental observations seems to indicate that the initial bolus shape is also
related to the fluid velocity exiting the needle and the stability of the syringe. A higher
injection velocity resulted in the injected solution to travel further into the vitreous and
further deviated from an expected sphere bolus. The vitreous is a paucicellular hydrogel
with primarily unbranched type II collagen fibrils and hyaluronic acid.

These fibrils

form a tensioned semi-random polymer network, where the hyaluronic acid sustains the
tension by osmotic (Donnan) swelling. Investigations of the elastic shear moduli using
observations of spherical cavity instability of injected fluids into the vitreous cavity have
indicated that this tensioned structure is relatively easy to disturb and that the
déstructuration is strain rate (i.e. fluid velocity) dependent.30 In addition, the fulcrum of
the needle is the entry point of the sclera, which will effectively magnify any movements
o f the individual performing the injection. Thus the insertion of the needle, subsequent
movement, outflow velocity and instabilities in the vitreal collagen network will all lead
to the observed asymmetry o f the boli.
For potential changes to be made to the delivery method of ocular drugs it is important to
understand and address the factors in drug delivery that can be altered. Drug loss as a
result of reflux has been shown to be a highly variable factor in ocular drug delivery. It
has been estimated that

10%

loss o f drug could be substantial enough to alter the

pharmacokinetics and therefore effectiveness in treating the disease . 1 Work has been
completed recently that found the use of 30G needles and a deep injection helps to
minimize reflux of drug during intravitreal injections. 1 The study showed that with minor
modifications to injection supplies and technique, significant improvement can be made
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to administering the drug in the expected manner, thereby maximizing the therapeutic
effect. Our work has broadened and enhanced these observations with direct spatial and
temporal visualizations of the drug boli and associated phenomena following injection.
This is also the first work to date that has imaged an intravitreal injection while
maintaining the needle inserted in the eye. Limitations of the work associated with
injection flow rate is that it was a preliminary study that had only one specimen per group
with use of the syringe pump. To determine statistical differences further work would be
required. This experiment provided the necessary understanding of what is required to
administer an injection using a syringe pump and better understand what effect flow rate
has on intravitreal injections.

4.5

Conclusions

The observation and study o f intraocular air bubbles, inconsistent bolus shapes and flow
rate variations have demonstrated the importance of a consistent and accurate injection
technique to administer the appropriate concentration of drug to the retinal tissue. They
also suggest that the design and length o f the needle and the injection fluid velocity must
be carefully considered while administering intravitreal drugs, as this can alter the
concentration and period of drug reaching the target site. Pharmacokinetic modeling
assumptions must closely resemble clinical scenarios to provide the most meaningful
results and this work has helped to develop a greater understanding of the asymmetrical
initial bolus. It is only by making these anomalous features known and studying injection
parameters that they can be better addressed to improve the efficacy of intravitreal drug
delivery and perhaps influence the design of new drug delivery systems, all of which will
improve patient outcomes and safety.
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Chapter 5
5

Modeling drug transport in the vitreous using
computational fluid dynamics

This chapter explains the development o f a computational flu id dynamics model fo r drug
flo w in the vitreous body. Model geometry and transport properties are based on those
fo u n d in ex vivo experimentation using micro-CT. Validation o f the model is completed
by using the ex vivo experimental results presented in earlier chapters. The modeling
presented is a simplified system o f ocular drug flow using diffusion based transport
analysis.

5.1

Introduction

Developing new drugs and drug delivery systems for the posterior segment o f the eye has
become a great interest of vision research. Computational modeling o f drug flow is
progressively being used in the quest for finding a method that requires fewer injections
and provides more targeted delivery. CFD modeling allows for a variety o f tests to be
performed without using animal or human models. It provides a method o f testing and
insight into the pharmacokinetics o f delivery systems such as controlled release
implants, controlled release drugs and polymeric delivery systems. Recent studies have
incorporated MRI imaging with model development, but focused on new drug delivery
strategies, such as iontophoresis,4’5 rather than intravitreal injection.
Initial models of intravitreal drug delivery were developed using the simple geometry of
a circle to represent the vitreous with retinal permeability being the only boundary
condition .6 Several studies were developed upon these results and added fluid models
beyond diffusion, such as Navier-Stokes7,8 and Darcy’s Law .9 CFD models have been
developed to study drug distribution in the vitreous following intravitreal injections.
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Based on the results of the injected fluorophores in frozen sections of vitreous, a finite
element model of the rabbit eye was created to study drug distribution after intravitreal
injection of fluorescein-based compounds.

n

Models were developed further by

incorporating the lens and interaction with the anterior portion of the eye (aqueous
humour and iris) . 7 Friedrich et al. used their model to determine the importance of
position and volume of intravitreal injections and found that elimination and distribution
o f drug was significantly affected by the injection location. 10 Further work was
completed and found drugs travelled much faster in aphakic eyes (i.e. the absence of the
lens) and retinal permeability is an important parameter to consider in understanding drug
distribution in the vitreous. 11 All of this work demonstrated the complexity and need for
better understanding of ocular drug flow following intravitreal injections, but very little
has been validated by experimental evidence.
A major portion of work related to modeling ocular drug delivery has used the rabbit eye
as a model . 1,7,12 Rabbit eyes are very common in ophthalmic research for their similarity
in size and properties to that of the human eye. However, rabbit eyes have a very large
lens and as a result a much smaller vitreous volume than humans. When studying ocular
drug flow in the vitreous, using a rabbit model, reduced vitreous volume is important to
consider. Boundary interaction and distances to travel are also key variables to consider
when developing a model that has the potential for human applications.
The purpose of this work is to develop a CFD model of a porcine eye using the model
geometry and diffusivity values from micro-CT imaging. Validation of the model will be
completed using the micro-CT acquired images of intravitreal injected contrast agents
into the vitreous. It is anticipated the non-invasive imaging will provide important
temporal and spatial background information to develop the fluid dynamics model
resulting in a more complete understanding of ocular drug flow in the vitreous.
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5.2

Methods

Model geometry, meshing and finite element modeling was performed within a
commercially available software package (COMSOL Multiphysics, COMSOL Inc.,
Burlington MA). A 2-dimensional (2D) model was designed to validate the diffusion
model and material properties. This 2D model was designed to be expanded to a 3dimensional (3D) model that would maintain all of the same parameters.

5.2.1 Initial Conditions
An intravitreal injection was modeled as a hemi-spherical or tear drop bolus with a
uniform concentration (Equation 5.1),
Ct=o =

10

mol/m 3

for intravitreal inj ection

(5.1)

The hemi-spherical shape was chosen because it is the initial bolus shape in previous
works studying ocular drug flow in the vitreous and is a common clinical assumption.
The hemi-spherical bolus was based on a symmetrical sphere of 30 pi volume, resulting
in a 3.86 mm diameter. The tear drop shape was designed based on the experimental
results found in the micro-CT study which demonstrated the initial bolus resembles a tear
drop shape more often than a sphere. The dimensions of the tear drop bolus were 0.74
mm at the top, where the needle tip would be located, and 3.48 mm at its widest point
near the bottom. The initial concentration everywhere else in the simulation was set to
zero (Equation 5.2),
Ct=o = 0

everywhere outside the drug source

(5.2)

5.2.2 Governing Equations
A purely diffusive model was designed to replicate the transport mechanisms occurring in
the ex vivo experiment. To expand upon this model a convective component was added to
represent what may be found for an in vivo animal model. To determine the convection
transport of the drug, the Navier-Stokes equation (Equation 5.3) was used to solve the
flow components of the vitreous humor. Navier-Stokes equations solve for the fluid
motion using pressure, density and viscosity as parameters. The velocity results were then
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coupled with the convection-diffusion transport equation to determine the distribution of
drug concentration (Equation 5.4).
p U V U = - V P + rjV2U

(5.3)

— + U V C = D V 2C
dt

(5.4)

where p is the mass density, U is the velocity vector, P is the pressure,

77 is

the viscosity,

t is time, D is the diffusion coefficient and C is the concentration of the drug. It was
assumed there was no drug reaction, degradation or retardation (due to surface effects),
so these were not included in Equation 5.4.

5.2.3 Model Geometry
The geometry o f the porcine model was based on a simplification of the micro-CT
images acquired in the study. The thickness of the retina could not be calculated from the
micro-CT imaging, therefore it was taken from literature . 13,14 Table 5.1 provides details
o f the dimensions used in the formation of the porcine model and Figure 5.1 shows the
final geometry used.

Table 5.1 Dimension for model eye
Geometric dimensions of the porcine eye used in the computational fluid dynamics
model.
Tissue

Parameter

Value (mm)

Vitreous body

x-semiaxis
y-semiaxis

10.00
10.75

Lens

x-semiaxis
y-semiaxis

3.50
5.00

Retina

thickness

0.15

Anterior chamber

thickness

2.00
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Sclera

Hyaloid
Membrane

Lens

Y
A

Retina
X <-----

Figure 5.1 Domain of vitreous transport model
Porcine eye model geometry and finite element mesh with labeled anatomical features
that were included in the model and the injected bolus shape/position. Dots (•) indicate
points where measures were taken to represent concentration levels at the macula and
bottom of the eye.

5.2.4 Boundary Conditions and Material Properties
Continuity was assumed for convection-diffusion in all regions except those impermeable
to the drug. For the surfaces assumed to be impermeable to the drug, lens and sclera, a
zero species gradient was used,
ÔC
— =0

at lens and sclera

(5.5)

dn

The hyaloid membrane and a small region of the anterior chamber were included to
determine the concentration of drug that entered the anterior segment o f the eye.
Anatomically the hyaloid membrane is the boundary between the vitreous and anterior
chamber. It is composed of highly porous tissue, therefore no resistance was included in
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the transport properties. Material properties were estimated or obtained from the
literature. The values are shown in Table 5.2. Diffusion coefficients were obtained
experimentally and calculated from the micro-CT imaging. Average diffusion
coefficients obtained in the results of the micro-CT study were used since they provide a
wider range than estimated values from Wilke-Chang or Stokes-Einstein. The inflow
source was restricted to the pressure of the anterior chamber acting as a normal
component. The vitreous outflow rate across the retina was calculated based on the area
o f the retina of a typical porcine eye used in the ex vivo work and an outflow rate from
literature.

Table 5.2 Model parameters for CFD model
Material properties and model parameters used in the pharmacokinetic model.
Constant

Value

Reference

Diffusion coefficient of iodine

4.76x1 O'6 cm2/s

Calculated in this
study

Diffusion coefficient of gold
nanoparticles

9.07x1 O'6 cm2/s

Calculated in this
study

1 g/cm3

Kaufman e t a/.15

1.406 g/cm3

Nath e t a/.16

Density of gold nanoparticles

1 g/cm3

Estimated

Dynamic viscosity of vitreous

0.00629 Pa-s

Stocchino e t a/.17

0.002 Pa-s

GE Healthcare18

0.000911 Pa-s

Nanoprobes19

2000 Pa

Stay e t at.2

4.67x10-3 cm/hr

Araie and Maurice6

Density of vitreous
Density of iodine

Dynamic viscosity of iodine
Dynamic viscosity of gold nanoparticles
Intraocular pressure
Vitreous outflow through retina

5.2.5 Solution Method
The model geometry was automatically meshed using the built-in software function to
create triangular elements throughout the domains. Finite element method was used to
solve the model, where discrete elements are solved using differential equations. To solve
the computational model, Equation 5.3 was first solved

to determine the velocity
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distribution in the vitreous using Navier-Stokes equation. The solution was assumed to be
time-independent and therefore unaffected by the action of the diffusing drug mimic. The
resulting velocity field was exported and used in the time-dependent diffusion-convection
equation (Equation 5.4) to solve for the concentration distribution of the drug mimic in
the vitreous. All simulations were run on a 2 GHz Core 2 Duo CPU running Windows.

5.3

Results

5.3.1 Validation of Model with Experimental Results
The maximum drug concentration is assumed to be at the center of the bolus. Time
dependent measurements were taken from both experimental and modeling cases and are
shown in Figure 5.2. For the purpose o f this validation, the initial concentration of the
bolus in the simulation was set to 150 mg/ml to correlate with the iodine solution
concentration used in the ex vivo experiment. A strong correlation was found between the
two and the model was well within the margins of error from the experimental results.

160

•

------- Modeling (CFD)

140 -

E
O)

E

CO

120

-

100

-

Experimental (imaging)

80 60 -

o

O

40 20

-

0 -I---------------- r0

50

T---------------------------------------------1---------------------------------------------1

100

150

200

Time after injection (min)

Figure 5.2 Concentration at the center of the injected bolus
Numerical model validation with ex vivo experiment data of concentration values at
center of bolus up to 2 0 0 minutes post-injection, using measured values from
experimental contrast agent in micro-CT imaging (dots) and CFD modeling (dashed line).
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5.3.2 Effect of Diffusion Coefficients
Diffusion coefficients used in the model were chosen as the two extremes for the contrast
agents under study. In Figure 5.3, the model predicted concentration profiles are shown
for the time point of 3 hours, the end point of experimental work completed using microCT. The profiles indicate due to the small differences in the diffusion coefficient, the
maximum concentration of iodine within the eye remains at 1.7 times greater than for
gold nanoparticles. The area of greatest importance is the back of the eye, or the macula.
Figure 5.4 provides greater information into concentration at specific points by depicting
the model-predicted concentration gradients for (A) iodine solutions and (B) gold
nanoparticles at specific points in the eye of the macula and bottom retina. Iodine had the
lower diffusion coefficient and resulted in longer period for the model to reach uniform
concentration throughout the entire vitreous. The model was run for a simulation of 24
hours and iodine had still not reached uniform concentration within the model eye. Gold
nanoparticles had a higher diffusion coefficient and reached uniform concentration more
rapidly after approximately 15 hours. However, the iodine remained at a slightly higher
concentration at the macular for a longer period of time than the gold nanoparticles.
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A

Max: 1.626
1.626
1.544

1
1.465
1.385
1.306
0.908
1.226
0.829
1.147
0.749
1.067
0.67

0.59
0.511
0.431
0.352
0.272
0.193
0.113
0.033
Mr: 0.0331
Max: 0.940
1.94
1.902

B

1.864
1.826
1.788
1.75
1.712
1.674
1.636
1.598
i.56
1.522
1.484
.446
.408
.371
.333
.295
.257
.219
.181
Min: 0.181

Figure 5.3 Concentration profiles from CFD model
Model predicted concentration profiles for A) iodine solution (4.76 x 10'4 mm 2/s) and B)
gold nanoparticles (9.07 x 10"4 mm 2/s) at 3 hours post-injection. Units for the
concentration profiles are mol/m3.
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A

B

Figure 5.4 Concentration gradient at boundary points for contrast agents
Differing diffusion coefficients were used in the model between A) iodine solution (4.76
x 10‘4 mm 2/s) and B) gold nanoparticles (9.07 x 10‘4 mm 2/s). Boundary points are located
at the macula (back of the eye) and bottom of the retina/eye.
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5.3.3 Air Bubbles and Bolus Shape
To determine the extent to which air bubbles and asymmetrical initial bolus shape were
responsible for ocular drug flow, CFD modeling was completed for each of the scenarios.
For air bubble analysis, the model was adapted by adding two air bubbles, one of average
size and the other of maximum size recorded from the ex vivo porcine experiments. The
one of average size was positioned at the top of the bolus and the larger one at the
bottom. For bolus shape the model was adapted by using a tear drop shaped initial bolus
rather than a hemispherical. Figure 5.5 provides the concentration gradients found at the
macula as a result of these simulations. A direct comparison can be made with the graphs
found in Figure 5.4B to understand what changes occurred with the presence of air
bubbles or an asymmetrical initial bolus. The air bubbles resulted in no significant
change, however the tear drop bolus shape resulted in a higher peak concentration at the
macula than the hemispherical bolus shape.
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/ \
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20

25

Time (hrs)

Figure 5.5 Concentration gradient at the macula for anomalous features
Model simulations were performed with the presence of air bubbles around the initial
bolus (dotted) and with the initial bolus in the shape of a tear drop (dashed). Diffusion
coefficients used in the simulation were for gold nanoparticles (9.07 x 10‘4 mm 2/s).
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5.3.4 Convection
The results of the convection-diffusion model simulations showed that the distribution of
the injected solution reached uniform concentration more rapidly with the presence of
convection, but concentration profiles remained very similar to those shown in Figure
5.3. Most interestingly, the concentration of the injected drug at the macula remained at a
higher concentration for a longer period. Understanding the affect an injected drug has on
the normal convective flow of the eye is also important. The convective flux is shown in
Figure 5.6 and demonstrates how the distribution of an injected solution, in this case gold
nanoparticles, is influenced by active flow. A non-uniform flow pattern is also influenced
as a result of the differences in viscosity and density of the introduced drug.
Max: 5.064e-9

xlO'9

15.064

4.479
4.244
4.008
3.772
3.536
3.301
3.065
2.829
2.593
2.358

2.122
1.886
1.65
1.415
1.179
0.943
0.707
0.472
0.236

'o
Min: 0

Figure 5.6 Convective flux and velocity fields in CFD model
Convective flux of the vitreous body is shown in the contour plot and velocity field is
depicted by the arrows with their respective magnitude. Units of the convective flux
profiles are mol/m 2 s.
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5.4

Discussion

A model was developed for simulation of intravitreal drug delivery in the vitreous body.
This model is unique from previous ones in that it is based on diffusion coefficients that
were obtained from extensive experimental data and studies anomalous features of
intravitreal injections. Developing a computational fluid dynamics model is a favourable
method in studying fluid transport, as parameters can be easily manipulated and
parametric studies performed. This model has been developed so that it can be used to
study other drugs and include additional parameters such as boundary permeability,
metabolism of drug and altered injection sites. A well-developed model can also be used
to minimize the number of animals used for in vivo experimentation by doing some of
the analysis using a CFD model rather than animal model. However, it is very important
to ensure the model has been developed and validated with high quality experimental
results.
The strong correlation between the CFD model and the ex vivo data as shown in Figure
5.2 is an indication that the model developed is representative of what is occurring
experimentally in porcine eyes when injected with contrast agent. A primary objective of
this work was to develop a simulation from a computational model that strongly
resembled the results found experimentally. Correlation of maximum concentration
values in part demonstrates the correct domain parameters have been set, such as
diffusion coefficient, density and viscosity. The model solutions also demonstrated strong
convergence with reciprocal of step size values ranging from 10'3 and 10‘4.
Detailed concentration contour profiles were obtained from the CFD model as shown in
Figure 5.3. These images provide the spatial information of how a drug is distributed
throughout the vitreous. Figure 5.4 provides specific point information within the
vitreous and comparison of the concentration at the target site, the macula, and a
peripheral region at the bottom of the eye. From these profiles we can see that the drug
reaches the macula quite quickly and peaks at approximately 5 hours. However, it is 7%
o f the concentration that was initially injected. That carries huge implications for drug
delivery and the potential to overdose healthy areas of the eye in order to reach sufficient
levels at the target site.
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Modeling based on the presence of air bubbles and altered bolus shapes revealed minor
deviations from the concentration gradients that did not have these features. Air bubbles
resulted in slightly higher peak values of drug concentration at the macula with 0.3%
more of the initial concentration than the normal. The teardrop bolus shape had more of
an effect and resulted in 1.1% more of the initial concentration at the macula than in the
case of a hemispherical bolus. The full extent of the asymmetrical bolus may not be
realized because the model is constrained to 2D and could result in larger differences in a
3D model.
Convection has been shown to be an important parameter to include in ocular drug
delivery studies, particularly for humans models.2 When a convective component was
implemented in this study’s model, the concentration profiles did not have much of an
effect when coupled with diffusion. This could be attributed to the fact that the molecular
weight of the drug mimic used in this study were much higher than those used in other
studies that cited convection as a significant transport mechanism. ’ However, by
creating this diffusion based model an important step has been made in learning more
about ocular drug delivery. It has been shown by Missel et al. that it is vital to separate
experiments to deduce diffusion from other transport mechanisms due to the nonlinear
way that they interact.

9 ft

A limitation of this model is that it lacks the 3D information that was provided in microCT imaging. However, the 2D model is simpler to design and implement in terms of
requiring less computational power and time. There are some limitations to the
quantitative data provided since homogenous properties of the vitreous and no lateral
diffusion/dispersion must be assumed. The third dimension that is missing from this
model would be side-to-side if you were looking into the eye from the front or back. This
direction is expected to have the same transport properties as the other horizontal
direction from front to back while boundary interaction would only be an issue at later
time points. The effect of gravity, particularly for high molecular weight drugs, could
also be introduced as a potential transport mechanism in the vertical direction as some
characteristics of it were displayed in micro-CT imaging.
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5.4.1 Translation to Human Model
CFD modeling allows for developed models to be easily translated to other applications
or systems. It allows for an intermediary step to be established between animal models
and human testing, by developing a CFD human model. Model geometry can be altered
to replicate that of the human eye and known material properties and boundary conditions
revised. The realized properties such as diffusion coefficient and density driven flow
would be maintained and applied to the human model. The results of such a simulation
would more closely resemble what may actually occur in a human eye. While the results
would be based on some assumptions, the efficiency and lack of requirements for human
subjects makes the research particularly appealing for drug delivery studies.

5.5

Conclusions

A computational fluid dynamics model has been developed based on parameters obtained
from experimental data. Results from the model correlated extremely well with those
found in the experimental results performed using porcine eyes. The model is able to
study the quantitative effects of diffusion or convection and the introduction of
anomalous features on drug concentration within the vitreous following an injection. The
model is an excellent resource to create a correlation between ex vivo and computational
experimentation and allows for model enhancements or adaptations to be made for future
work.
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Chapter 6
6

General Discussion and Conclusions

This chapter will provide a brief summary o f how each previously presented objective
was addressed in the research. Limitations o f ex vivo experimentation and the use o f drug
mimics will be discussed and means o f addressing each will be suggested. Potential
directions that this work can be carried out in the future are explored and the overall
significance o f the work completed is highlighted with potential clinical and research
contributions.

6.1

Summary

The ability to provide a greater understanding of drug distribution and fate of ocular drug
administration is vital information that can have major clinical implications. Intravitreal
injections are commonly used to administer drugs to the posterior segment of the eye, but
little is known as to how the drug flows through the vitreous once it has been injected.
Use of intravitreal injections for the treatment of AMD and other diseases continues to
increase as new drugs are developed and drug costs decrease or are covered by health
insurance.1,2 Toxicological impact and concentration levels of intravitreal injections is
important because the drug administered directly into the eye. Through the integration of
non-invasive imaging and computational modeling, new knowledge can be obtained to
aide in developing changes or alternatives to the current method of drug administration.
To visualize the progression of drug flow through the vitreous in micro-CT imaging, two
contrast agents were compared as possible drug mimics. Iodine solutions have a very low
molecular weight and have been well studied in biological systems.4,5 Gold nanoparticles
have a molecular weight that is similar to that of some anti-VEGF drugs used in AMD
therapy, but is a relatively new contrast agent for x-ray imaging.66 A variety of testing

88

was performed on each of the contrast agents including concentration calibration, dilution
from the vitreous over time and diffusivity, to determine if gold nanoparticles were a
viable alternative as a drug mimic for intravitreal injections. It was found that gold
nanoparticles can be used at lower concentrations for an extended period o f time to
maintain sufficient contrast over iodinated solutions and possess a closer molecular
weight to intravitreal drugs.
Micro-CT imaging of drug mimic flow through the vitreous allows for spatial and
temporal concentration profiles to be obtained. This important information allowed for
accurate diffusivity estimates to be made using Crank’s passive diffusion equation and
CFD. In addition, time dependent differences in diffusion coefficients led to the
examination of how the drug interacts with the domain boundaries. The use of an animal
model allows for insight into the mechanisms of ocular drug transport and the use of
specialized equipment and experimental configurations that would not be possible in
human subjects. Furthermore, ex vivo testing allows for evaluation and optimization of
the experimental methods without the use of live animals.
Complications or abnormalities that develop as a result of intravitreal injections are
important aspects to be considered when studying ocular drug flow. It was shown in the
ex vivo experiments that typical intravitreal injections are likely to result in anomalous
features. These can include air bubbles, the initial bolus taking on the form o f irregular
shapes and differing flow rate of the injection, all of which may impact drug delivery.
This is the first work that has addressed any of these unexpected characteristics, in part
due to the unique set up of non-invasive imaging. As a result this could help develop
more accurate pharmacokinetic computational models.
Using the knowledge gained from the ex vivo specimens imaged using micro-CT and
analyzed for passive diffusion, a porcine eye model was designed for use in CFD
modeling. Model dimensions were values measured from the micro-CT images and
assumptions used in previous models, such as bolus shape, were revised to account for
what was found from the imaging. Diffusion coefficient values that were calculated in
earlier work were used within the model and resulted in a strong correlation with the
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experimental concentration results. Spatial and temporal dependent drug concentration
was the outcome o f interest. The necessity to separate transport mechanisms

was

successfully accomplished using ex vivo data and allowed for a strong understanding of
the diffusive nature of ocular drug flow in the vitreous. The developed model provides a
strong foundation for expansion into a more complex 3D and constitutive CFD models
o f ocular drug flow in the vitreous.

6.2

Limitations

All experimental work presented here utilized ex vivo porcine and rabbit eyes. This is an
obvious limitation as it does not allow for a full understanding of ocular drug transport
within the vitreous because of the absence of any active flow. A pilot in vivo experiment
was performed with an anesthetized rabbit and syringe pump. Significant problems
occurred with needle positioning and stability in addition to the challenge o f the small
bore size of the micro-CT. These experiments would be possible if a custom designed
micro-CT bed was designed to hold the rabbit and position the syringe. Preliminary
drawings have been designed for this set up and may be employed in future work.
Despite the inability to acquire in vivo data, it is now fully understood what is required in
future work if an in vivo setup is desirable.
Radiopaque contrast agents were required for the injected solution to be detectable in the
micro-CT scans for an extended period of time at a measurable concentration. The two
contrast agents utilized, iodine and gold nanoparticle solutions, were classified as drug
mimics for this work. They were used because pharmaceutical drugs used in intravitreal
injections would not be detected in the micro-CT imaging as they do not possess the
radiopaque properties required to be viewed from the background or vitreous grey scale
intensity. Therefore, it cannot be assumed that clinical drugs would act in exactly the
same manner as the contrast agents when flowing through the vitreous. An important
aspect of this work was understanding the properties of the contrast agents and
commonly used intravitreal drugs. From this it was inferred that gold nanoparticles would
act in much the same way as the most common intravitreal drugs.
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6.3

Future Work

Important steps of this work have been completed and have provided a strong foundation
for further work to be completed. Minimum concentrations levels of the contrast agents
studied have been established for future work to balance sufficient signal intensity with
cost. Gold nanoparticles provide a variety o f options with the ability to tag drugs and/or
dyes to the nanoparticles. This would provide the option to study the drug’s presence by
multiple imaging modalities and provide insight into how the drug interacts with the
retinal tissue once it reaches the posterior boundary of the eye.
Micro-CT imaging an in vivo rabbit model would provide the additional active flow and
clearing behaviour absent in the presented experimental data. Diffusion has been shown
to be a major contributing factor, if not the principal factor, in drug transport in the
vitreous. With the knowledge gained from the ex vivo data analysis, the method to
deconvolve diffusive flow is now known and would play an important role in
understanding the degree to which active and passive flow play a role.
Advanced CFD modeling could be employed by creating a fully developed 3D model of
the animal model eye, porcine or rabbit. This model could be used to better understand
the full effect the drug properties have on ocular drug flow. Specifically, to investigate
the effect of density, viscosity and molecular weight on drug flow and develop
recommended prescribing information for a drug with a particular set of properties to
ensure the required concentration reaches the target site for a sufficient amount of time,
while not reaching levels of toxicity. Development of new administration methods of
drugs to the vitreous is gaining popularity and this model could be adapted to understand
where the ideal location for drug administration.
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6.4

Significance

The ability to accurately model drug transport following an intravitreal injection provides
vital information to better understand the concentration and time frame for the drug to
reach the target site. By addressing anomalous features not otherwise studied, the work
provides insight into potential variation that exists between clinically administered
intravitreal injections and those modeled in pharmacokinetic studies. The approach of
creating a link between experimental pharmacokinetic data found from non-invasive
imaging with CFD modeling makes this work unique and novel. The findings permit the
development of more accurate predictive tools or models to better understand and
optimize ocular drug delivery. These tools can be used to provide the medical community
and industry with the ability to design and test new drugs and drug delivery systems for
clinical application.
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Appendix A - Eye Planes/Orientation
To help understand the orientation and use of planes for the eye in this study, Appendix
A provides a slice and label for each plane. The lens is labeled in each image it is visible
and the cornea is depicted with an arrow. The axial plane refers to a top down view where
all sides can be seen. The coronal plane refers to the plane from one side to the other or
what one would see looking into the eye or from the back. The sagittal plane refers to a
side on view of the eye where you can see from the front of the cornea to the back o f the
retina.

Axial

Coronal

Sagittal

/
Lens
Lens

Figure A .l Planes used for orientation of the eye in analysis of micro-CT images
The arrow indicates the cornea and the lens is labeled.
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Appendix B - Contrast Agent ROIs
An example of the 3D regions of interest (ROIs) based on concentration levels of the
contrast agent/drug mimic in the vitreous are shown in Figure A.2. The ROIs are
representative of grey scale intensities and are from time points of 8, 48 and 192 minutes
post-injection, from smallest to biggest.

Figure B.l Isosurfaces representing the diffusing bolus over time
The red surface represents 8 minutes post-injection, the blue 48 minutes and the yellow
192 minutes.
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Appendix C - Contrast Agent Bolus Signal Profiles
Examples of signal profiles obtained from the micro-CT images are shown below for two
specimens used in calculating the diffusion coefficients.
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Figure C .l Line signal profiles through the bolus
Signal intensity vs. distance taken at each time point in the x (horizontal), y (vertical) and
45° directions for A) 150 mg/ml iodine in sagittal plane B) 150 mg/ml coronal plane C)
37 mg/ml in sagittal plane D) 37 mg/ml in coronal plane.
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Appendix D - MATLAB Implementation Code
Custom made MATLAB optimization code for calculating curve of best fit with diffusion
coefficient variable.
% C alculates th e p r e d i c t e d c o n c e n t r a t io n v a lu e s u s in g th e p a s s iv e
d iffu s io n
% e q u a t i o n (C r a n k ) b a s e d on t h e d i s t a n c e i n p u t .
%
%Where:
%I = i n t e n s i t y l i n e p l o t ; Co = i n i t i a l c o n c e n t r a t i o n ; V =
i n j e c t i o n volum e;
%D = d i f f u s i o n c o e f f i c i e n t ; t = t i m e s i n c e i n j e c t i o n
%
% C re a te d b y CAS on 0 4 - D e c - 0 9 .
c le a r a l l
clo se a l l
% global r ;
% g l o b a l Co;
g lo b a l t ;
% g l o b a l a;
%Load t x t f i l e
filen a m e = in p u t ( 'E n t e r
I = lo a d (file n a m e );

file

name:

','s');

% Re q u ir e d u s e r i n p u t v a l u e s
%Co = i n p u t ( ' E n t e r v a l u e o f Co: ' ) ;
t = i n p u t ( 'E n t e r va lu e o f t (sec): ' ) ;

o
II

% D e f in e d v a l u e s
10 = I ;
d = I (:,1 ) ;
Co = 4148;
%t = 28 80;
V = 30;
a = ( (V *3)/ ( 4 * p i) ) A (1 /3 );
DO = 4E-4 ;
xmax

% C a l c u l a t e FWHM & SD
w id th = f w h m ( I ( : , 1 ) , I ( : , 2 ) ) ;
SD = w i d t h / ( 2 * s q r t ( 2 * ( l o g ( 2 ) ) ) ) ;
SD1 = ( 0 . 5 * w i d t h ) + S D ;
SD2 = ( 0 . 5 * w i d t h ) + ( 2 * S D ) ;
SD3 = ( 0 . 5 * w i d t h ) + ( 3 * S D ) ;
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%C e n te r d i s t a n c e v a l u e s a b o u t z e r o
[M,N] = m a x ( 1 0 ) ;
dmax = 1 0 ( N ( 1 , 2 ) , 1) ;
r = I ( : , l ) - ( d m a x + l E - 1 0 ) ; %cannot ha v e r = 0 b / c NaN w i l l
r e t u r n e d and o p t i m i z a t i o n t e r m i n a t e d

% C a l c u l a t e w in d o w
p l o t ( r , I ( : , 2 ) ) ; h o l d on ;
p lo t(x m a x + S D l, 0 :2 0 0 0 /' r : ' , xm ax-S D l,0 :2 0 0 0 ,' r : ' ) ;
p l o t ( x m a x + S D 2 , 0 : 2 0 0 0 , 'b : ' , x m a x - S D 2 , 0 : 2 0 0 0 , 'b: ' ) ;
p lo t ( x m a x + S D 3 , 0 : 2 0 0 0 , ' g : ' , xmax-SD3,0 : 2 0 0 0 , ' g : ' ) ;
h o ld o f f ;
%d = I ( : , 1 ) ;
d i s p ( ' S e l e c t a l e f t p o i n t and r i g h t p o i n t t o d e f i n e
w i n d o w . 1) ;
I = I (: / 2) ;
[Wl,W2]=ginput(2);
low=find(r>Wl(1),1, 1first1);
high=find(r<Wl(2),1,1last1);

be

the

r = r(lo w :h ig h );
I = I (lo w :h ig h );
p l o t ( r , I)
% p lo t( r (lo w :h ig h ), I ( lo w : h ig h ) )

% C a lcu la te background
p l o t (10);
d is p ( 'S e le c t p o in ts to c a lc u la te
ENTER k e y when d o n e . 1) ;
[p x ,q y ] = g in p u t;
back = mean(qy);

% Signal i n t e n s i t y
s ig n a l
1 = 1 - back;

is

a background average.

Press

d e fin e d by rem oving u s e r - d e f in e d background

%D = l s q c u r v e f i t ( ' C r a n k 1, DO, r , I ) ;
[D ,re s n o rm ,re s id u a l,e x itfla g ,o u tp u t,la m b d a ,J ]
l s q c u r v e f i t ( ' C r a n k 1, D O , r , I ) ;
C = C ra n k(D ,r);
D
% C a lcu la te c o e f f i c i e n t o f d e t e r m in a t io n
MeanY = m e a n ( I ) ;
R2 = 1 - ( s u m ( ( I - C ) . A2 ) / s u m ( ( I - M e a n Y ) . A2 ) )

=

98

% P l o t o b s e r v e d and p r e d i c t e d r e s u l t s
p l o t ( r , I , ' k - ' , r , C , 1k : ' )
l e g e n d ( 1O b s e r v e d ' , ' P r e d i c t e d 1)
x l a b e l ( 1D i s t a n c e f r o m c e n t e r (mm)1)
y l a b e l ( 'C o n c e n t r a t io n (AU)')

on t h e same g r a p h

% Use NLPREDCI t o f i n d c o n f i d e n c e i n t e r v a l s on t h e m o d e l ' s
response
[ y p r e d , d e l t a ] = n l p r e d c i ( ' C r a n k ' , r , D , r e s i d u a l , ' j a c o b i a n ' , J) ;
Cl = m a x (d e lta );
% P lo t the confidence i n t e r v a l s
C a r e t h e SAME!
fig u re
p lo t (r,yp re d )
h o l d on
p l o t ( r , I , ' + r ')
p lo t(r,y p re d + C l , ' — g')
p lo t(r,y p re d - C l , ' — g')
%Ou tpu t m a t r i x
OUTPUT = [ t , V, b a c k , m i n ( r ) ,
c l i p b o a r d ( ' c o p y ' , OUTPUT);

w it h th e o r i g i n a l data —

max(r),

D, R2,

ypred &

C l]

Function for passive diffusion equation from Crank (1975) used in Optimization code
fu n c tio n

F = C rank(D ,r)

global t
% Defined v a lu e s
Co = 4148;
V = 30;
a = ( (V*3)/ (4*pi))A (1/3);
DO = 4 E - 4 ;

F = ((1/2).*(Co).*(erf((ar ) ./(2.*(sqrt(D.*t))))+(erf((a+r)./(2.*(sqrt(D.*t)>>)))>((Co./r).*(sqrt((D.*t)./pi)) .* ((exp((-((a-r).A2)) ./(4.*D.*t))(exp( (-((a+r).A2))./(4.*D.*t))))));

